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GLOSSARY
ACS – acute coronary syndrome
AWMI – anterior wall myocardial infarction
AW+LWMI – anterior wall and lateral wall myocardial infarction
CAD- coronary artery disease
CAG – coronary angiogram
ECG- electrocardiogram
HTN- hypertension
HSP- heat shock protein
HSP 60 heat shock protein 60
hsCRP – high sensitivity C reactive protein
IWMI – inferior wall myocardial infarction
IWMI +PWMI – inferior and posterior wall myocardial infarction
MI – myocardial infarction
PCI – percutaneous coronary intervention
PWMI – posterior wall myocardial infarction
RDA – recommended dietary allowance
STEMI – st elevation myocardial infarction
T2DM – type 2 diabetes mellitus
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TITLE : ROLE OF INFECTION AND INFLAMMATION IN
ACUTE CORONARY SYNDROME
BACKGROUND :
The relation of infection with acute coronary syndrome is ever
contradictory.Many antibiotic trials have failed in treating acute coronary
syndrome.We have planned to focus on the concept of molecular mimicry
between infectious agents and human proteins leading to inflammation and thus
clinical syndromes of atherosclerosis secondary to these inflammatory reactions
mounted against human antigens.One such preserved hyman chaperone is HSP
60 from prokaryotic age which shares molecular mimicry with many viral and
bacterial human shock proteins.When inflammation is mounted against these
HSP,the released inflammatory cascade molecules cause atherosclerosis and/or
plaque destabilization and acute coronary syndrome.
AIM:
To study the role of infection in activating inflammatory pathwasy in the
pathogenesis of atherosclerosis and acute coronary syndrome
OBEJECTIVE:
T o evaluate the role of bacterial and viral infection as a risk factor for STEMI
through analysis of circulating levels of heat shock protein 60 in ACS patients on
comparision with controls without ACS
To measure level of inflammation with high sensitivity c reactive eprotein and to
evaluate its relation with HSP 60 and traditional risk factors of ACS.
METHODOLOGY AND RESULTS :
Ours is a case control study with 333 STEMI cases and 27 controls without ACS are
studied.Traditional risk factors for ACS are assessed in both groups along with
measurement of HSP 60 and hsCRP . HSP 60 and hsCP are considered to be
indirect markers for infection and inflammation respectively.HSP60 is measured
through spectrometric method analyzed through ELISA while hsCRP is read
through automated COBAS analyzer. In cases further evaluation of features of
echocardiography and coronary angiogram are studied.We found that circulating
levels of hsCRP has statistical significance in cases(p<0.05) while levels of HSP 60
donot have significant p value but have ODDS ratio of 1.54 indicating the
possibility of relation of infection with incidence of acute coronary syndrome and
its outcome.On regression analysis of all traditional risk factors for ACS they donot
seem to influence the levels of hsCRP and HSP 60 in cases and controls in a
statistically significant manner.
1INTRODUCTION
In field of medicine large amount of clinical spectrum of diseases in relation to
cardiovascular system are secondary to inflammation. Infection also has a significant role
through activation of inflammation. The role of inflammation is evident by the
pathological processes involved in initiation and progression of atherosclerotic plaques.
This can also lead to conversion of stable atherosclerotic plaque in the vascular tree to an
unstable plaque and can cause an acute event clinically. This highlighted the importance
of inflammation in vascular disease. For a stable plaque to be converted to an unstable
plaque leading to clinically significant thrombotic event even a low grade inflammation is
sufficient.
The role of infectious agents as Cytomegalovirus, Human papilloma virus,
Enterococcus, Chlamydia species, Mycoplasma, Influenza and other microorganisms has
been studied till now in many studies in relation to acute coronary syndrome. But their
role has not yet been applauded widely because of contradictory findings in various
antibiotic trials.
High sensitivity C reactive protein, has been associated with atherogenesis and
causation of acute coronary syndrome by foam cell formation, endothelial disruption and
complement activation. Many studies have explained hs CRP level deviation on par with
presenting symptoms and the degree of plaque disruption.
The arterial wall is subjected to various dynamic forces and insults. Heat shock
proteins are seen in a number of physiological processes in the arterial wall and are
classified based on molecular weight. Heat shock protein 60 is a mitochondrial protein
located in cytoplasm, mitochondria and plasma. Under conditions of stress, this molecule
comes out and mediates apoptosis via immune mechanism activation and antibody
2production. By molecular mimicry mechanism ,when infection occurs, production of
antibodies against these infectious agents act on heat shock proteins too which can be
simultaneously released during disease associated stress conditions or hemodynamic
alterations. This causes plaque instability leading to acute coronary syndrome. Many
viruses, bacterial infection(Chlamydia, Helicobacter pylori) mount a autoimmune
response in blood vessel and establish role of infection in inflammatory cascades involved
in atherosclerosis.
However, role in acute coronary syndrome  has to be established in  developing
countries like India where rate of infection is rampant. In our study, we intend to evaluate
the role of infection through measuring HSP 60 level in plasma causing activation of
inflammation(through measuring hs CRP) and leading to acute coronary syndrome
independent of traditional risk  factors.
3TITLE OF THE STUDY:
Role of infection and inflammation in acute coronary syndrome.
AIM OF THE STUDY:
To study about the role of infection in activating inflammatory pathways in the
pathogenesis of  atherosclerosis and acute coronary syndrome.
Primary Objectives:
 To evaluate the role of bacterial and viral infection as a risk factor  for STEMI
through analysis of circulating levels of heat shock protein 60 in Acute Coronary
Syndrome patients in comparison with subjects without Acute Coronary
Syndrome in 20 to 80 years age group
 To measure the level of circulating inflammatory marker, high sensitivity C
reactive protein and  to analyze its levels on comparision with HSP 60 levels, to
evaluate the relation between infection and inflammation leading to plaque
disruption and Acute Coronary Syndrome
Secondary Objectives:
 To correlate the inflammatory markers levels with the coronary angiogram,
Echocardiographic and electrocardiogram findings in subjects with Acute
Coronary Syndrome
 To study the relation & independent risk evaluation of the traditional risk factors
in comparison with markers of inflammation and infection(HSP-60,hsCRP) in
cases and controls
4National Significance with Rationale:
India being a developing country ,has increasing incidence of infectious disease
burden and acute coronary syndrome .Cardiovascular diseases are leading cause of
mortality in our nation.
The analysis of role of infections in ACS through inflammatory pathways has to
be evaluated in Indian population.
Our study will be the first study to evaluate both viral & bacterial infections role
in ACS in relation to inflammation in South India.
JUSTIFICATION:
The role of inflammation in acute coronary syndrome has been proven. However
the role of infection in acute coronary syndrome has not yet been proven and the earlier
antibiotic trials in acute coronary syndrome patient have failed. Here is a trial to justify
the role of infection in relation to inflammation in acute coronary syndrome patients
which can explain the reason for the failure of antibiotic trial and explain the molecular
mimicry mechanism of infection leading to acute coronary syndrome.
OUTCOME MEASURES:
Role of infection in acute coronary syndrome through evaluation of circulating
levels of heat shock protein-60 Evaluating relation between traditional risk factors and
infection and inflammatory markers Measure the differences in values of these markers
among cases and controls Coronary angiogram, echocardiographic and electrocardiogram
findings relation with these circulating infectious and inflammatory markers
5REVIEW OF LITERATURE
1. Acute Coronary Syndrome(ACS):
Acute coronary syndrome is a unifying term representing a common end result
,acute myocardial ischemia. It encompasses acute MI (resulting in ST segment elevation
or non ST segment elevation electrocardiographically) and unstable angina.1.This
definition is important clinically in deciding the treatment option for the patient.2.
2.Clinical Presentation:
Acute ischemic pain ,lasting for over 20 minutes ,associated with inadequate
supply of blood to heart muscle due to plaque rupture, fissuring, erosion or a combination
with superimposed intracoronary thrombus is 80% of times presenting clinical features in
ACS.1,2.  Unlike stable angina even minimal exercise or even at rest ischemia can occur.
The pain may be intermittent and accompanied by diaphoresis, nausea, abdominal pain,
syncope and dyspnea.3.Uncommon symptoms may include epigastric pain, indigestion,
stabbing chest pain and they are more varied in diabetes, women, heart failure patients.
As per Thygesen et al, universal definition of MI based on causative agent, five different
types of MI have been classified.4.This classification is based on symptoms,
electrocardiographic changes or cardiac biomarker elevation.
63. Clinical Classification of Different Types of Myocardial Infarction:
TYPE     DEFINITION POSSIBLE CAUSATIVE AGENT
I Spontaneous infarction due Primary coronary event
To  dissection Plaque rupture,
erosion, fissuring and
II         Secondary infarction due Endothelial dysfunction, coronary spasm,
to ischemic imbalance embolism, anemia, arrhythmias, respiratory
failure, hypertension, hypotension
III Cardiac Death
IVa PCI
IVb Stent thrombosis
V CABG
7Classical classification of ACS as adapted from Hawn et al and Nikus et al as follows,
Acute Coronary Syndrome
↓                                                             ↓
Persistent ST elevation No persistent ST elevation
↓                                                          ⁄                            ↓
Troponin rise/fall         No change in Troponin                 Troponin rise/fall
↓ ↓                                               ↓
STEMI            Prevented cardiac damage   Unstable angina  NSTEMI
As per Valentin Fuster et al, the term ACS first appeared in 1986 on a simple Pub
Med search in an article describing the flow characteristics of coronary balloon
catheters.6.As time evolved in 1992 ACS term included MI, unstable angina and ischemic
sudden death.6.All these are part of spectrum of manifestations of the same
atherosclerotic coronary artery substrate. These definitions have now evolved into a
definition as described above as per 2012 iteration of the universal definition, which gives
importance to the measurement of Troponin I or T.As reflected by both GRACE(Global
Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial
Infarction),biomarker negative patient are generally at lower risk for adverse
events.7,8.Hence,we are planning to include STEMI patients as the case population in this
study.
84. Pathogenesis of Acute Coronary Syndrome:
As per Filippo Crea and Giovanna Liuezzo, pathologically ACS can be classified into, 9
 Patients who have obstructive atherosclerosis and systemic inflammation
 Patients who have obstructive atherosclerosis without systemic inflammation
 Patients without obstructive atherosclerosis
This is important in view of varied clinical presentation of ACS as described
above. Additionally a popularly being thought not always ACS is associated with
activation of inflammation as evident by the observation that about 40% of the patients
with ACS have low or very low levels of hs-CRP(high sensitivity C reactive protein),a
very sensitive marker of inflammation.
Hence we are interested in evaluating the role of inflammation in our study in
ACS(STEMI) patients. Our study is also intended to highlight the concept of ACS with
obstructive atherosclerosis without systemic inflammation by evaluation of physical,
emotional and possible environmental stressors which would be responsible for ACS by
evaluation of these risk factors in our cases. The concept of obstructive lesions with
systemic inflammation occurs by activation of innate and adaptive immunity.9.In our
study we are focusing on the concept of chronic infection acitng as antigenic stimulation
and activating the adaptive and later innate immunity through disease associated
molecular pattern(DAMPS) activation of T cells in ACS.
5. STEMI Definition:
As per third universal definition of MI,STEMI is majorly  defined based on
electrocardiographic findings4. It is described as new ST elevation at the J point in two
contiguous leads with the cut points ≥0.1 mV in all leads other than leads V2-V3,where
9the following cut points apply:≥0.2mV in men ≥40 years & ≥0.25mV in men < 40 years
or ≥ 0.15 mV in women.
The ECG pit falls leading to false positives  can be(which are exclusion criteria in
our study)
 Early repolarisation
 LBBB
 Pre excitation
 J point elevation syndrome e.g. Brugada syndrome
 Pericarditis/Myocarditis
 Pulmonary embolism
 Sub arachnoid hemorrhage
 Metabolic disturbances such as hyperkalemia
 Cardiomyopathy
 Lead transposition
 Cholecystitis
 Persistent juvenile pattern
 Malposition of precordial ECG electrodes
 Tricyclic antidepressants and phenothiazine intake
The causes of false negatives like,
 Prior MI with Q waves and or persistent ST elevation
 Right ventricular pacing
 LBBB
Are all considered as exclusion criteria in our study.
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6. Global Burden of ACS:
Ischemic heart disease ranks in first place as the cause of mortality and for the loss of
disability adjusted life years(DALYS) world wide, accounting for 7 million deaths and
129 million DALYS annually.14 A significant loss in economy occurs due to
cardiovascular disease accounting to 1/3rd of $47 trillion of total loss in economy due to
non communicable disease for the coming 20 years.14.Nearly 2/3rd of all IHDS,DALYS
and more than half of deaths occur in low and middle income countries. Witnessing the
epidemiological transition from the age of pestilence and famine , to age of receding
pandemics to age of degenerative and man made disease, to age of delayed degenerative
disease and to the on going age of obesity and inactivity helps us to explain the rise in the
risk factors leading to IHD especially in low and middle income countries.
Rapid urbanization, mechanization of transport and increasingly sedentary jobs in
low and middle income groups have led to an acceleration and overlap between the stages
of epidemiological transition. Ever since 1990, the number of deaths and DALYS
attributable to IHD  have risen.15
This acceleration in the rise of NCDS without a decline in the infectious disease
burden, has led to a challenging double burden of disease in many countries, especially in
developing nations 14. Through our study we want to analyze the relation between the
infectious disease and cardiovascular disease.
7. National and Local Burden of ACS:
In India ,cardiovascular disease is an important cause of mortality and morbidity.
Data from the Registrar General of India reported greater age adjusted cardiovascular
mortality in southern and eastern states of the country17. Coronary heart disease mortality
is higher in urban population than in rural population as per Rajeev Gupta et al study 17. It
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has been reported that there were significant regional variations ,with high CVD mortality
in Goa, Tamil nadu, Andhra Pradesh and Punjab and low mortality in central states of
Uttar Pradesh,Madhya Pradesh and Rajasthan. As per Shraddha Chauhan and Dr.Bani
Tamber Aeri, CVD in India ranks first among top 5 causes of deaths in Indian population
and the future trend analysis done by them indicated that 60 % of the worlds heart disease
population, including CHD, would live in India by 2015.19.There are no detailed reports
on CVD mortality by the Indian government. WHO has predicted that from years 2000 to
2020 DALYS from CHD in India shall double in both men and women from 7.7 and 5.5
million respectively.
India lacks data on cardiovascular risk factors obtained from prospective
cardiovascular epidemiological studies. However multiple case control studies exist. The
largest of these case control studies is the INTERHEART study 16. This study reported
that standard risk factors such as smoking, abnormal lipids, hypertension, diabetes, high
waist hip ratio, sedentary life style, psycho-social stress and lack of consumption of fruits
and vegetables explained more than 90% of acute CHD events in South Asians. In our
study we intend to evaluate the role of infection as a risk factor in addition to the
assessment of the standard risk factors.
As per Vamadevan S.Ajay and Dorairaj Prabhakaran India is in the midst of the triple
burden of diseases, the unfinished agenda of communicable disease linked with life style
changes and emergence of new pathogens and overstretched health infrastructure. Hence
through our study we intend to find the role of these infectious diseases through a
circulating marker called heat shock protein-60 in causing plaque disruption in ACS
patients.
12
8. Pathophysiology of Coronary Atherosclerosis and Acute Coronary Syndrome:
Carl Rokitansky and Rudolph Virchow ,in the mid 19th century discovered the role
of inflammation in atherosclerosis 12. Rokitansky suggested that the intiating step of
atherosclerosis was caused by the accumulation of blood derived products in the arterial
wall and inflammation was caused by the accumulation of blood derived products in the
arterial wall and inflammation was the reaction to the accumulated lipids 12. Rudolph
Virchow ,in turn, suggested that the inflammatory reactions were the preliminary step 12.
In the 1970’s Russell Ross proposed the response to injury hypotheses highlighting
endothelial injury, smooth muscle cell growth and lipid hypotheses in atherosclerosis 13.
Thus atherosclerosis is seen as an inflammatory disease including various cell types and
lipoprotein metabolism.
Although the inflammatory reactions are accepted to be involved in all stages of
atherosclerosis progression, the debate on the initiating step is still on-going.
Our study is aimed at focusing infection as the initiating step of inflammation
which can casue or aggravate atherosclerosis leading to ACS.
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9. Atherosclerosis and Thrombus formation:
Atherosclerosis usually develops in the context of elevated risk factors.
Figure 1
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Figure 2
SCHEMATIC EVOLUTION OF ATHEROSCLEROTIC PLAQUE
Accumulation of lipoprotein particles in the intima
↓
Oxidation and glycation of these particles
↓
Local oxidative stress increases
↓
Local cytokine /circulating elevation of cytokines causing inflammation
↓
Leukocyte migration into intima by increased expression of adhesion molecules for
leukocytes and chemoattractant molecules
↓
Monocytes enter artery wall in response to cytokines(il-8,mcp-1)
↓
15
Form macrophages by action of macrophage colony stimulating factor and augmented
expression of scavenger receptors on macrophages (e.g.CD163)
↓
Uptake of modified lipoprotein  through these scavenger receptors and form foam cells
↓
Small areas of endothelial desquamation occurs leading to microthrombi formation
↓
Platelets in microthrombi form mediators for SMC migration(PDGF),collagen
synthesis(TGF-BETA) and inhibit fibrinolysis
Foam cells produce cytokines, HOCL, superoxide anion and MMPS
↓
Smooth muscle cells migrate into intima from media and divide and form fibro-fatty
plaque with lipid laden macrophage debris and extracellular lipid- cholesterol esters and
cholesterol monohydrate crystals
↓
Calcification can occur and fibrosis continues accompanied by SMC death
Leading to protective fibrous cap production
↓
Neo vascularisation occurs in response to acid fibroblast, vascular endothelial growth
factor—breeches in the vessels cause micro thrombosis(marked by hs -CRP)
↓
Collagen accumulation and increase in size of thrombus
↓
Those with fissured fibrous cap, numerous mononuclear phagocytes, large lipid pools
↓
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Increased macrophages tend to have increased tissue factor
↓
Local denudation of endothelial cells  occurs with or without intact endothelium
Apoptosis of endothelial cells is promoted by inflammation
Endothelial cells express MMPS in response to oxidized lipids/oxidative stress and
inflammatory mediators
Local cholesterol crystallization in relation to shear stress promotes activation of NLF3
pathway and increases inflammation (il-1)
Plasmin generated by PA degrade components of arterial extracellular matrix and activate
MMP-2
Proteolysis causes fracture of cap
Decreased de novo synthesis of smc and hence collagen decreases leading to plaque
destabilization
T cells are activated in thrombus release IFN-GAMMA which decreases collagen
synthesis by smc and trigger smc apoptosis
** Oxidative stress and inflammatory pathways play a decisive role in destabilization of
the plaque that triggers thrombosis in both superficial erosion and fibrous cap rupture.
↓
Plaque ruptures or erodes and coagulation cascade starts and forms thrombus
17
10. ACUTE CORONARY SYNDROME:
As influenced by various risk factors, the instable plaque on disruption forms
thrombus breaking the coronary artery and causing acute coronary syndrome with STEMI
on ECG. Clinically these cases present with prior symptoms of Angina pectoris, or other
peripheral vascular diseases like having intermittent claudication.
During the acute episode, the chest pain that occurs is classically an exaggerated
version of angina pain where the patient is unable to even move in the bed and has a
feeling of loss of life, vomit and defecates. The pain is retrosternal, radiating to left arm
commonly but can radiate to any part above umbilicus and below the jaw. This pain is
due to activation of nerve endings from dying myocardium. Cold sweats, palpitations,
giddiness and sudden severe weakness can be a part of the presenting symptomatology.
The pain of MI, before presentation has to be differentiated from
1. Pleural pain
2. Pulmonary embolism
3. Acute aortic dissection
4. Oesophagi is/Gastritis
5. Costo chondritis
6. Pericarditis
However, clinicians have to keep an entity called silent MI in mind, especially
while dealing with diabetes and hypertensive group of population. These patients
outcome is however no different from the other STEMI cases
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Physical Examination:
These patients look conscious and have a rolled fist at their chest, a clinical sign
known as the divine sign. However, when patient has massive MI, involving the majority
of left ventricle, these patients present with severe dyspnoea and will be uable to lie down
flat. Similarly patients who present with cardiogenic shock are presenting a total calm
attire with no movement and have a pallor at the cord extremities and face and have
cyanotic nails and lips.
These patients have a heart rate elevation, however can also present with total
absence of pulse or bradycardia. Many patients without complications of STEMI have
normal blood pressure. Patients. Patients can even present with elevated blood pressure
due to worry, which leads to pressures greater than 160/90mmHg. These patients due to
LV dysfunction, inspite of having hypertension earlier can present with low BPand for
these patients to return back to their hypertensive range will take three to six months post
MI. when patients are in shock, their BP may fall to undetectable levels. This hypotensive
presentation is more common with inferior wall MI, due to parasympathetic activation.
The body temperature may rise and the patient can have fever which lasts for four to five
days. The elevation of body temperature can be a part of inflammatory processes in the
body.
When the infarction involves the right ventricle, on examination of the neck veins,
the juglar vein is distended and feature of tricuspid regurgitation like elevated a-v wave is
evident. The prominence of a wave as a feature of LV dysfunction causing pulmonary
hypertension can occur in STEMI patients. The carotid pulse has to be palpated to
evaluate,
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1. Severe LV dysfunction- pulse alterations
2. Mitral regurgitation/ ruptured ventricular septum- sharp upstroke which is short in
duration.
The auscultatory findings were used by Kimball and Killip in 1967 to classify
patients  into the following classes which explains us the mortality rate in cases, with
class IV having the worst prognosis
Killip Class I- No features of pulmonary edema, hemodynamically stable
Killip class II- pulmonary edema evident by basal rales on auscultation
Killip class III- with complications,S3,pulmonary edema(>10cm from diaphragm rales+)
Killip class IV – cardiogenic shock
Systemic Examination:
Palpitation in uncomplicated cases is insufficient but at times reveals S3 and S4.
On auscultation, S1 (first heart sound) becomes soft and sometimes a reversal splitting of
second heart sound occurs. S3 and S4 are heard in patients with severe LV dysfunction
and are heard the best in the mitral area. When the MI occurs in the right ventricle S3 and
S4 are best audible in the left lateral sternal border. An holosystolic murmur is heard at
the apex radiating to axilla and back due to dysfunction of the papillary muscle and
causing mitral regurgitation. Doctors should also concentrate on the auscultatory findings
of ribs of pericardium due to all strata infarction.
Palpation of the abdomen may reveal congestive hepatomegaly, but always there
need not be an increase in the size of the liver. Patients can have altered sensorium or
neurological weakness secondary to embolic phenomenon. Examination of fundus for
changes secondary to hypertension or diabetes has to be assessed.
20
ECG Findings:
STEMI as above is defined for classification , but the location of blocked artery
can be assessed by lead involvement.
Left anterior descending artery:
It is one of the major branches from the left coronary artery and gives rise to first
diagonal branch and the latter to first septal branch. Occlusion of LAD before these
branches arise give rise to ST elevation in leads V1-V4 and leads I and aVL. It can be
associated with RBBBand at times with ST elevation in leads aVR. Blockage of LAD
between diagonal and septal branch causes STEMI changes in V1 to V4
Figure 3
21
Figure 4
Complications of Anterior wall MI
1. Ventricular fibrillation/ Ventricular Tachyarryhthmias
2. Intraventricular conduction defects
3. Right bundle branch block
4. Left bundle branch block
5. Complete AV block
6. LV dysfunction and heart failure
7. Sudden cardiac death.
Left circumflex Artery:
When thrombosis occurs in this artery ST elevation occurs in leads aVL and I or
V5 and V6 with reciprocal changes in V1 to V3. When LCX supplies or becomes
posterior descending artery ST elevation is seen in II, III and aVF showing involvement
of inferior wall.
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When posterior wall is affected, ST depression is seen from V1 to V3 with tall R
wave in V1 and V2 and leads placed in V7, V8 and V9 show ST elevation. In the
definition of STEMI only exception to height of elevation is seen in this type of MI,
where even an elevation of 0.5mm is considered to be STEMI, as the heart is distant from
these leads V7-V9 which picture the posterolateral aspect of the heart.
Complications of Posterolateral/Lateral STEMI:
1. Ventricular Fibrillation and ventricular Tachycardia
2. Left ventricular Dysfunction
3. AV block, when the dominant artery of the heat is left circumflex artery
Right coronary artery:
Plaque rupture and occlusion of this artery causes inferior wall MI seen as ST
elevation in leads II, III and aVF at times with V5 and V6 involvement. When reciprocal
changes are seen in V1, V2 and V3 the possibility of posterolateral MI has to be ruled
out.
Figure 5
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Complications of inferior wall Mi:
1. Varying degrees of atrioventricular block is commonly seen
2. Ventricular tachycardia , ventricular fibrillation – rare
3. Intraventricular conduction defects – LBBB, RBBB with associated greater
incidence of asystole, atrioventricular block, ventricular fibrillation and
cardiogenic shock. All these features are associated with extensive involvement of
myocardial tissue.
4. Acute severe mitral regurgitation secondary to rupture of posteromedial papillary
muscle, as this is supplied by right coronary artery only. This is a very serious
condition.
5. Right ventricular STEMI: Whenever we find inferior wall MI, right sided ECG
has to be taken to check STEMI in right sided leads of ≥ 1mm. As the changes of
right ventricular MI last only for a transient period of approximately one hour, it
should be mandatory to take right side ECG in all cases of inferior wall MI. The
hemodynamic abnormality seen in right ventricular MI can be hypotension with
distended neck veins (jugular vein) and lungs without crackles. These set of
patients have positive Kussumaul sign.
Investigations:
1.Routine blood investigations like complete blood counts, serum creatinine,
blood urea, blood sugars, serum fasting lipid profile
2.Urine routine
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3.Cardiac biomarkers like Troponin T, CK-MB
4.Echocardiography – Figure 6
Treatment:
1. Thrombolytic therapy
2. Loading dose with high dose antiplatelet and statin
3. Anticoagulation with unfractionated heparin or low molecular weight heparin
based on presence of complications like LV clot, pulmonary embolism
4. For ongoing pain – nitroglycerin (when BP > 90 mm Hg & pulse rate > 50
beats/min)
5. Supplemental oxygen therapy
6. Morphine sulphate for pain relief
7. Beta blockers in the absence of complications like prolonged pr interval,av
conduction block, bradycardia.
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8. ACE inhibitors/ARBS
9. Diuretics in case of failure or fluid overload stages
10. Percutaneous coronary intervention – primary or elective.
11. Intraaortic balloon pump therapy
12. Intraventricular conduction devices
13. Newer drugs like ivabradine, vasopressor, inotropes are other treatment options
based on clinical presentation.
Figure 7a & b
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Figure 7c
Figure 7d
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11.Risk Factors for Atherosclerosis and ACS:
A risk factor refers to any attribute characteristic or exposure of an individual,
which increases the likelihood of developing a non communicable disease.
As per the INTERHEART study the attributable traditional risk factors for ACS
are hypertension, diabetes mellitus, dyslipidemia, elevated waist hip ratio, obesity,
smoking, alcohol consumption, decreased physical activity, decreased consumption of
fruits and vegetables, psycho social stress incidence is elevated in Indian population.
RISK FACTORS Tab.1
Traditional Risk Factors
Atherogenic diet
Obesity
Age
Gender
Family History
Diabetes Mellitus
Systemic Hypertension
Dyslipidemia
Smoking/ Alcohol
Stress
Physical Activity
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In our study we intend to evaluate all the traditional risk factors through standard
definitions and scales as given below,
 Current Smoker or tobacco user : Person who smokes either daily or occasionally
 Current Daily Smoker or tobacco user : Person who smokes either daily or
occasionally except on special religious occasions
 Past Smokers : Persons who have stopped smoking from past 12 months
 Non-Smoker : Person who has never smoked in their life time
 Current Drinker: Person who drinks daily or occasionally in the past one year
 Former Drinker: Person who had not consumed alcohol daily or occasionally in
the past one year but has consumed prior to it
 Complete Abstainer: Person who has never consumed alcohol
 Binge drinker : Person who drinks alcohol daily of more than five drinks in case
of men and more than four drinks in case of women
 A drink is defined as standard drink if ethanol content is more than 10gm
 Dietary habits: As per 24 hour recall method (questionnaire attached below)
 Physical Activity : IPAQ method of assessment (attached below)
1)Inactive : No physical activity
Novel Risk Factors
Lipoprotein a
Inflammation
Infection
Oxidative stress
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2) Minimally active : 3 or more days of extensive activity for a minimum of 20
minutes every day
Or 5 or more days of moderate activity atleast for 30 minutes per day
3)HEPA activity : Vigorous activity spending 1500 MET minutes/week
 Metabolic Equivalent (MET): It is calculated as a ratio of individual’s metabolic
rate between his activity rate and resting rate.
1) At rest MET : It is equal to spending 1kcal/kg/hour
2) At working  MET: It is equal to spending 4kcal/kg/hour
3) At vigorous activity MET : It is equal to spending 8 kcal/kg/hour
 Central Obesity: It is defined based on the waist circumference and hip
circumference and the ratio between two or the waist circumference alone.
Central obesity is calculated based on measuring this value in the mid axillary line
between the inferior coastal margin and superior iliac crest with a foldable tape.
As per ATP III guidelines:
>102 cm in males
>88 cm in females
As per South Asia Pacific Guidelines:
>90 cm in males
>80 cm in females
Weight is classified as follows as per WHO guidelines,
 Underweight :  A person is said to be underweight when the BMI <18.5kg/m2
 Normal Weight :A person is said to be normal weight when the BMI between 18.5
and 24.9kg/m2
 Overweight : A person is said to be overweight when the BMI is > 25 kg/m2-
29.9kg/m2
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 Obesity : A person is said to be obese when the BMI is >30kg/m2
 Hypertension : In simple terms it is elevated blood pressure.In our study we
considered blood pressure to be elevated when patient is a known hypertensive on
antihypertensive medication or has blood pressure of systolic/diastolic
>140/90mmHg
Tab.2
Stages of Blood Pressure SYSTOLIC/DIASTOLIC
Stage 1 Hypertension ≥140-159 / ≥90-99
Stage 2 Hypertension ≥ 160 / ≥100
 Diabetes mellitus: When overt hyperglycemia manifestations are absent diabetes
is defined as per ADA 2013 guidelines if,
1) HbA1C ≥6.5
2) FBS ≥ 126mg/dl and PPBS ≥ 200mg/dl
 Dyslipidemia: AHA 2013 guidelines are followed for ASCVD risk factor
assessment and defining dyslipidemia
Individuals
1. Clinical manifestations of vascular disease,
2. Initial elevations of LDL–C >190 mg/dL,
3. Diabetic patients ( age group 40 to 75 years) with LDL–C 70 to189 mg/dL and
without clinical vascular disease, or
4. Without clinical ASCVD or diabetes with LDL–C 70 to189 mg/dL and ASCVD
risk >7.5%
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Clinical ASCVD  is said to be clinical evidence of peripheral arterial disease,
coronary vasculature diseases or cerebral vasculature disorders. All inclusive apart from
genetic or hereditary lipoproteinemias.
However these are the recent guidelines, but we have considered ATP III
guidelines in our study where
Tab.3
LDL INFERENCE
<100 Normal
100-129 Near Normal
130-159 Borderline elevation
160-189 Elevated levels
>190 Very elevated levels
HDL cholesterol levels of <40 are considered low while levels >60 are considered
as high.
Tab.4
TRIGLYCERIDES
<200 Normal
200-239 Borderline elevated
>240 High
When risk factors are present these interventions are taken into consideration
based on those coronary heart disease risk factors
1) Cigarette smoking
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2) Hypertensive  >140/90mmHg or on antihypertensive medication
3) Low HDL <40
4) Family History of Coronary artery disease where first degree male relatives have
coronary heart disease by  <55yrs and similarly first degree related women of age
<65 years age
Based on these risk factors dyslipidemia can be inferred as follows. Usage of
Framingham risk score based on these risk factors can also be taken into consideration.
Tab.5
Risk Categorisation LDL levels
CAD or CAD risk equivalents ≥ 100mg/dl
2 or more risk factors ≥130mg/dl
0 or one risk factor ≥160mg/dl
 Psycho social stress: Gold berg scale (bedside test where set of questions are
asked)
Tab.6
POINTS ANSWERS
0 Not felt so
1 Feels a bit so
2 Somewhat feels so
3 Feels intermediately so
4 Feels quite a lot like that
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Tab.7
TOTAL SCORE SUMMATING
ALL ANSWERS
INFERENCE OF LEVELS OF
DEPRESSION
0-9 NO
10-17 POSSIBLE
18-21 MINIMAL
22-35 MILD – MODERATE
36-53 MODERATE
54 & ABOVE SEVERE
As per Integrated disease surveillance project of non communicable disease risk
factors survey in Tamil Nadu done in 2007 – 2008 by ICMR concluded that smoking is
the leading risk factor for non communicable dieases in Tamil Nadu and that physical
inactivity is the leading casue for hypertension, diabetes mellitus and coronary artery
disease 6.
An review of traditional risk factors in CAD and evaluation of novel risk factors
like lipoprotein a, oxidative stress, infection and inflammation is essential to define the
reason for early onset of plaque destabilization in young population.1,3,12.
Lipoprotein a denotes a subclass of LDL characterized by an apo B moiety
covalently bound to apolipoprotein a.apo B  is the initiating molecule in atherosclerosis
plaque formation. Genome –wide association studies and mendelian randomization
studies support a causal role for Lpa in atherothrombosis 12.
Oxidative stress through oxidation of LDL has a proven role in the pathogenesis
of atherosclerosis. Inflammatory cells in the plaques especially macrophages contain
enzyme myeloperoxidase can generate potent oxidant species like hypochlorous acid and
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mediate tyrosyl residues chlorination in lipids. Such modification causes  production of
oxidized lipids which are taken up by macrophages and can also impede reverse
cholesterol transport mediated by HDL 12.
The other novel risk factors as inflammation and infection are discussed in detail
in below sections. In our study we are aiming to evaluate the traditional risk factors in our
study and control population through above standardized methods and find the dominant
risk factor in people visiting our hospital. Along with these non modifiable risk factors for
ACS like age and sex are also planned to be evaluated in our study.
11. Role of Inflammation In ACS:
A growing body of evidence points to inflammation as a primordial driver of all
stages of atherothrombosis. Peter Libby and Filippo Crea clinical review on JUPITER
trial highlighted the fact that people in the group with below median LDL and below
median C-reactive protein had no demonstrable benefit from statin treatment while the
group with below median LDL and above median C-reactive protein enjoyed the benefit
from statin therapy, highlighting the importance of inflammation in the absence of overt
dyslipidemia in cardiovascular diseases.27.Filippo Crea and Giovanna Liuzzo in their
paper on pathogenesis of ACS stated that in patients with ACS and systemic evidence of
inflammation had widespread coronary inflammation evidenced by activation of
neutrophils in the cardiac muscle not supplied by the artery responsible for ACS. This
feature is not seen in coronary atherosclerosis or recurrent ischemia causing chronic
stable angina and multivessel coronary disease or in vasospastic angina patients.9.Hence
they highlighted the fact that the widespread acute coronary inflammation is the likely
cause for, multiple stenoses, multiple thrombi and multiple fissured plaques involving
different coronary artery branches. This fact is proven by many angiography and
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intravascular imaging studies which had even measured the circulatory inflammatory
markers.28-31.Such concept of ACS with obstructive atherosclerosis and systemic
inflammation is confirmed by postmortem studies.
Figure 8
As discussed above two mechanisms precipitate ACS, a rupture of the plaque’s
fibrous cap and superficial erosion of the intima. The former mechanism being most
fatal.56
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Antigens   +  Dendritic  cells
↓
Activate TH1 lymphocytes
↓
Produce IF gamma
↓
Activate macrophages which have TLP 2 & 4, which
Bind to damage associated molecular pattern and pathogen
associated molecular patterns
↓
Release of proinflammatory cytokines
↓
Plaque ruptures and forms red thrombus
↓
Polymorphonuclear leukocytes in thrombus increase
oxidative stress(MPO) and mast cells release il-6 and IFN-gamma
↓
Trigger systemic inflammation and hepatic acute phase response
↓
High sensitivity C- reactive protein
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A study highlights the fact that advanced plaques have a defect in the clearance of
apoptotic cells leading to their accumulation ,a process called mummification because of
a defect in efferocytosis. These cells release procoagulant tissue factor which triggers
thrombus formation in the disrupted plaques 33.
Peter Libby, Ira Tabas, Gabrielle Fredman and Edward A. Fisher highlighted the
importance of specialized pro resolving medications(SPMS) which play an important role
in resolution of inflammation without causing immune suppression by reducing
efferocytosis in atherosclerotic plaque and thus by avoiding ACS.
Through our study we intend to prove the role of systemic inflammation
irrespective of lipid abnormalities, which is provoked by chronic infection causing release
of heat shock protein -60 which acts as DAMP and augments atherosclerosis to ACS.
12. High Sensitivity C-Reactive Protein and Atherosclerosis:
C-reactive protein is a pentraxin acute phase protein, members of which are
evolutionarily conserved in most vertebrates 40. CRP is produced by hepatocytes, smooth
muscle cells and macrophages in response to inflammatory cytokines including IL-1 and
IL-6.Ehrin J.Armstrong, David A.Morrow  and Mark S.Sabatine have stated in their paper
that CRP is a stable clinical marker because of its stability, reproducible results and ease
of assay. They also stated that CRP remains elevated for upto 3 months in one set of ACS
patients and other set shows slow decline during hospital stay itself. Sano T et al have
stated that in ACS patients the CRP levels correlate with the presence of plaque rupture,
as assessed by intravascular ultrasound 41.
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Figure 9
Crea et al stated that the number of disrupted coronary plaques correlates with
systemic hs-CRP levels and found that in ACS patients most of the times admission
values of ≥ 10 mg/dl.
In the PROVE-IT TIMI 22 trial it was found that patients treated with statin had
decreased hs-CRP values compared to admission values and had decreased mortality and
all these effects were independent of cholesterol levels 42. Excluding the conditions as
stated in the exclusion criteria for elevated inflammation and elevated hsCRP ,43,44 we
would like to study the level of systemic inflammation in ACS  cases and control
population. As stated in the US National Library of Medicine and National Institutes of
Health apart from CAD, CRP can be elevated in the following conditions which we will
be considering as exclusion criteria in both our cases and controls.
 Malignancy
 Connective tissue disorders
 Inflammatory bowel disease – Crohn’s Disease, Ulcerative Colitis
 Pneumococcal pneumonia – community / hospital acquired
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 Acute Rheumatic fever
 Joint abnormalities as Rheumatoid arthritis
 Pulmonary/Disseminated Tuberculosis
 History of intake of oral contraceptive pills in the past 6 months
 Pregnancy-3rd trimester.
13. Infection in Atherosclerosis:
Among the emerging risk factors, infectious agents both bacterial and viral agents
have received periodic attention as promoters of atherogenesis through the decades.
According to Peter Libby, Paul M Ridker and Kevin Croce, infectious agents might not
be involved directly in atherogenesis through local actions in the plaque but a
inflammatory response against these infections tips the homeostatic balance which favors
the thrombosis and decreases fibrinolysis through elevated production of IL-
6,plasminogen activator inhibitor-1.12.Such elevation of inflammatory cytokines causes
elevation of hsCRP a systemic marker of inflammation as discussed above.
Figure.10
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As written by Fiorella Calabrese et al in their editorial infectious agents causing
atherosclerosis plaque formation or rupture through activation of innate immunity
mechanism via Toll like receptors and activation of adaptive immunity via T cell specific
for antigens such as Chlamydia pneumonia, heat shock proteins or oxidized lipoproteins
52
.
As per Stephen E .Epstein et al, various pathogens like  Cytomegalo virus, Herpes
Simplex virus types 1 & 2,Chlamydia pneumonia and Helicobacter pylori, Hepatitis A
Enterobacteriaceae sps and periodontal pathogens to were found to reside in human
atherosclerotic plaques and seroepidemiological studies demonstrated an association
between pathogen specific antibodies and atherosclerosis 51. Pathogens always need not
reside in the body or in the plaque to cause atherosclerosis. The memory cell effect
secondary to infection and the autoimmune mechanisms and the propogation of
inflammatory cascade initiated by these agents is sufficient for atherosclerosis to occur in
human body.51,53.
This explains the fact why many antibiotic trials where antibiotics have been
prophylactically been given failed to prevent the occurrence of ACS. They are the
ROXID, STAMINA, AZACS, ANTIBIO trials which showed no benefit with
prophylactic antibiotics from preventing ACS. Epstein et al in their review article on
infection and atherosclerosis concluded that infection contribute to atherogenesis and its
acute complications ,however this in turn is determined by the hosts response to
infectious agent, the pathological burden of infectious agent the magnitude of host
inflammatory response to infectious agent and whether a host is predisposed to develop
an autoimmune response.  In our study we intend to check the hosts level of infection and
the inflammation caused by it which is hypothesized to be responsible for ACS. The
41
contribution of traditional risk factors in causing ACS has been planned to be evaluated in
our study to check the power of infection alone as risk factor for atherosclerosis. Such
studies are not done in our nation in South India, hence we intend to take this study.
Figure 11
14. Heat Shock Protein 60 as a marker for Chronic Infection in ACS:
Heat shock protein is a family of chaperone proteins with strong antigenic
properties with immunogenic and proinflammatory properties56. This stress protein is a
nuclear encoded protein found primarily in mitochondria54. M.Rabozynski in their study
a statistical significance between atherogenesis and elevated circulating antibodies to
hsp60 57. They explained that heat shock proteins are phylogenetically old cellular
protection system, which protects proteins from denaturation, determining the high
conservation of the amino acid structure of these proteins, which explains the homology
of these proteins of >70% in prokaryotes and humans. This homology enables the
possibility of cross reactive immune response to bacterial antigens with antigenic hsp of
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human cells.Iruna Cohen in 1990 and Wick et al first  explained this concept of antigenic
mimcry.58,59.
Figure 12
Although viruses do not express HSPs, as they proliferate within their host cells
and then break though host cell membrane to continue their life-cycle, host proteins can
be incorporated within the viral membrane.64,65. If such proteins include HSPs, as has
been shown, this would provide an explanation of how viruses, in addition to bacteria,
could evoke a HSP-based autoimmune response in the host.
Hence when once infected with bacteria and viruses with hsp60 body produces
antibodies to them. In conditions like increased shear stress, on exposure to nicotine,
elevated sugars, elevated temperature, the intracellular conserved human HSP 60 comes
to the surface because of the prokaryotic molecular mimicry the immune system
recognizes this human HSP 60 as pathogenis inview of earlier infection memory and
binds with it. As HSP 60 is expressed on endothelial cells, antigen presenting cells, T
cells and B cells all these are activated and the inflammatory cascade is set into force
enhancing plaque rupture and leading to ACS.A study by Zhang et al, identified a strong
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correlation between circulating levels of HSP 60 and the risk of CHD.54.Another study
by Luigi M Biasucci et al concluded that seropositivity for HSP 60 appeared to be highly
sensitive and specific marker for ACS independent of hs CRP and troponinT.56.Zhang et
al have found a positive correlation between hsp-60 and antibodies to hsp-60 in coronary
artery disease in Asian population. When detectable HSP 60 values are categorized as two
groups with low HSP 60(<1000ng/dl) and high HSP 60(>1000ng/dl).56.  As India is a
country with elevated infectious disease burden and ACS we want to evaluate the relation
between these two conditions in our study as there are no studies in South India based on
HSP 60,hsCRP and ACS.
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Study Area : PSG Hospital, Coimbatore
Study Population:
 Cases : STEMI patients diagnosed and being treated in PSG hospital
 Controls : Subjects visiting master health check up in PSG hospital without
evidence of acute coronary syndrome as per clinical symptoms and ecg
findings(as mentioned in the review of literature)
Study Time:
 As the samples for HSP 60 molecule can be stored for a maximum duration of 70-
80 days.The study collection of samples was done in that stipulated time.The
analysis of literature and molecule search and attainment of molecule with
laboratory standardization took the rest of the time.
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METHODOLOGY
Case Control Study
PSG Hospitals
↓
CASES(30-40)                                                                 CONTROLS(30-40)
Patients diagnosed as STEMI                               Master health check up &
satisfying the inclusion criteria                  visiting subjects without ACS
Clinical History,                                                   Clinical History,
Clinical Examination details, Clinical Examination details,
Evaluation of traditional risk factors,              Evaluation of risk factors,
Measurement of circulating hs-CRP &            Measurement of circulating
HSP-60 values, hs-CRP & HSP-60 values
Evaluation of  Echo cardio graphic findings*,
Evaluation of  per cutaneous coronary intervention findings(PCI)*
*Done by Cardiologist in PSG hospitals
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Inclusion Criteria:
Age: 20-80 years
Patients diagnosed to have STEMI with,(CASES)
 Symptoms clinically consistent with STEMI lasting >30 min
 Arrival at hospital within 12 hour of onset of chest pain
 ECG findings with new ST elevation from the J point in two contiguous leads with
≥0.1 mV in all leads except in leads V2-V3 where this features are applicable -
≥0.2mV in  ≥40 years men  and  ≥0.25mV in < 40 years  men or ≥ 0.15 mV in
women.
Controls will be subjects with,
 No symptoms of Acute coronary syndrome
 No features of Acute coronary syndrome on ECG (in the absence of LVH and LBBB)
 ST depression and T wave change - New horizontal or down-sloping ST depression
≥0.05 mV in two contiguous leads and/or T inversion ≥0.1 mV in two contiguous
leads- R/S ratio > 1 or prominent R wave.
Exclusion Criteria:
Pregnant females
Patients with
 Previous or recent ACS in past 3 months
 Severe Renal dysfunction
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 Concomitant inflammatory diseases (e.g. Rheumatoid arthritis, Inflammatory bowel
disease)
 Patient on immunosuppressive therapy
 Malignant tumor patients on chemotherapy and immunomodulators
 Electrocardiographic abnormalities which interfere with ST segment analysis
 False Negatives :
Pacing of right ventricle
1) Earlier myocardial infarction features like Q waves or ST elevation remnant
2) Q waves findings said to be associated with previous MI are ,
a) Q wave in V2-V3≥ 0.02 seconds or QS in V2-V3
b) Q wave ≥ 0.03 seconds and  ≥  0.1mV deep in leads I,II,aVL,aVF
c) In leads I,II,aVL,aVF or V4-V6 when QS complex is seen
d) In V1-V2 R/S ≥1 with positive concordant T wave or R wave ≥ 0.04 seconds
in absence of conduction abnormalities
 False positives for STEMI
 Wrong placement of leads while taking ecg
 Pulmonary thromboembolism
 Pericarditis
 Myocarditis
 Subarachnoid hemorrhage
 Electrolyte disturbances like hyperkalemia
 Acute cholecystitis
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 Cardiomyopathy
 Transposition of ECG leads
 Patient on drugs like phenothiazines or tricyclic antidepressants
DATA COLLECTION FORM
Name :
Age :
Sex :
Socio economic status : (as per Modified Prasad’s classification) Tab.8
SOCIO ECONOMIC
CLASS
INCOME PER MONTH PER
HEAD
I >Rs 5571/-
II Rs 2786-5570/-
III Rs 1671-2785/-
IV Rs 836-1670/-
V < Rs 836/-
Presenting Complaints :
Presenting History :
Past History :
Drug History :
Family History :
Personal History :
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General Examination  & Vitals :
Systemic Examination : (KILLIP CLASS I TO IV of STEMI patients based on the
extent of auscultatory rales as marker for pulmonary edema,S3 and presence or absence
of cardiogenic shock- based on cardiovascular and respiratory system examination)
Based on above findings TIMI RISK SCORE for STEMI patients is done in the following
manner (useful to assess 30 day mortality-as low risk0-2,and high risk-5-7)1,3.
- Age 65-74 yr/≥75 yr - 2/3 points
- Systolic blood pressure <100mmHg - 3 points
- Heart rate  > 100/min - 2 points
- Killip Class II-IV - 2 points
- Anterior STEMI or new LBBB - 1 point
- Diabetes,history of hypertension,history of angina - 1 point
- Weight  < 67 kg - 1 point
- Time to treatment <4 hr – 1 point
ECG findings : 3,4
Investigations:
- CBC
- Urine routine
- Serum Creatinine
- Blood Urea
- Serum electrolytes
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- TSH
- RBS,HbA1C
- Lipid Profile
- High sensitivity C reactive protein
- Human Heat shock protein 60
- Echocardiographic findings :Ejection fraction, Regional wall motion
abnormalities,clot,pericardial effusion,pulmonary arterial hypertension,valvular
abnormalities.1,3.
- Percutaneous coronary intervention findings 1,3 : Vessels involved,TIMI 0-3
SCORING based on angiography findings
- TIMI Grade 0 – No blush or minimal blush
- TIMI Grade 1 – Stain present.Blush persists on next injection
- TIMI Grade 2 – Contrast strongly persistent at end of wash out.Gone by next
injection
- TIMI Grade 3 – Normal ground glass appearance of blush.Contrast mildly
persistent at end of washout
Based on above findings risk factor assessment is done as follows :
I )Non modifiable risk factor
- Age
- Sex
- Family History of CAD/Diabetes mellitus/Systemic Hypertension/Dyslipidemia
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II) Modifiable risk factors (as defined in review of literature)
- Obesity & waist hip ratio (WHO 2004)
- Cigarette smoking
- Alcohol consumption
- Psychosocial assessment (Goldberg scale for depression)
- Dietary habits (24 hr recall method)
- Physical Activity(IPAQ questionnaire)
- Diabetes mellitus (ADA 2013 Guidelines)
- Systemic hypertension(JNC 8 Guidelines)
- Dyslipidemia and ASCVD risk score (AHA 2013 Guidelines for Dyslipidemia)
III) Emerging Risk Factors : hs CRP & Human HSP 60
Diet has been calculated as follows,
Recommended Dietary Allowance Tab.9
Nutrients Man Women
Sedentary Moderate Heavy Sedentary Moderate Heavy
Energy (Kcal) 2425 2875 3800 1875 2225 2925
Protein (g) 60 60 60 50 50 50
Diet history is calculated with 24hr diet recall questionnaire and the told diet history is
measured in possible standard measures and converted to calories.Such converted calorie
diet is compared with recommended dietary allowance and thus patient is considered to
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take high calorie or atherogenic diet when patient has taken diet above their
recommended dietary allowance.
Sample collection and Procedure details : Figure 13 & 14
Patient coming to Emergency department with chest pain
↓
Diagnosed as acute coronary syndrome – STEMI
↓
2.5 cc of blood drawn in 0.109 M Sodium citrate
↓
Immediately taken to lab and centrifuged at 3000
x g  for ten minutes and plasma is separated
↓
Store -20 for 70 to 80 days and is freeze thawed on day of
study
53
Methodology:
- Microplate wells have to be localised with human HSP 60 standard,2 hours to
incubate
- Wash five times with 200 micro litre of wash buffers manually with subsequent
decantation and loading
- Add 50 micro litre of biotinylated human HSP 60 antibody and follow 2 hours
incubation
- Then add streptividin peroxidase conjugate and incubate at 30 minutes
- Add chromogen 50 microlitre incubate at 30 minutes for blue colour followed by
stop solution for yellow colour change
- Read at 450nm of spectrometer and read as the level marked in filter
- Plot a graph with standard concentration on X axis and its absorbance on Y axis
- Sample concentration are obtained from curve and they are multiplied by dilution
factor to obtain value
- Values of HSP 60 >2ng/ml are considered to be significant from the test done.
- We ran samples of 33 patients and 27 controls on single day after standardization
with standard samples
High sensitivity C reactive protein :
C reactive protein being a acute phase reactant ,which is synthesized in liver and
released in conditions related to infection,inflammation and when patients have
underlying on going atherosclerosis.However all acute coronary syndrome patients donot
have elevated levels of hsCRP.
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2.5 ml of blood collected in plain bottle for serum separated from clot
immediately and analyzed promptly.Two reagents called R1 and R2 are used, where R1 is
TRIS buffer with bovine serum albumin and immunoglobulin and R2 is latex particles
coated with anti crp in a glycinated buffer.Sample collected is mixed with reagents and
kept in  a COBAS integra automatic analyzer,where automatically its calculated and
values are obtained.Values >0.5mg/dl are said to be significant.
STATISTICAL ANALYSIS
Case Control Study
- Sample size estimation = 2pq *7.83/d*d
- p is mean of prevalence of cases and controls (p1+p2/2),where p1 and p2 are
prevalence of cases and controls respectively
- q=1-p , d=p1-p2
- As per Biasucci LM et al study, hsCRP and Chlamydial HSP 60 were found to be
67% and 30% respectively in ACS patients and normal subjects.56
- Substituting these in the above formula sample size of case and control population
is estimated to be 28-30 each.
- Categorical variables were compared using a chi square test, Fisher exact test. The
independent variables(risk factors in the study) are compared with the dependent
factor( HSP 60 and hs CRP) using multivariate regression analysis and the results
are tabulated. All analyses used two sided tests with significance level of
p=0.05.Data were analyzed using SPSS version 16.0 for windows (SPSS ,Inc,
Chicago, IL,USA)
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RESULTS
In our study we focused to evaluate the relation of various traditional risk factors
with markers of inflammation and infection which are hsCRP and HSP 60.We have
analyzed the data in relation with novel risk factors for ACS like inflammation and
infection by measuring circulating levels of hsCRP and HSP 60 respectively with possible
traditional risk factors.
The traditional risk factors are evaluated are,
1. Type 2 diabetes mellitus
2. Hypertension
3. Dyslipidemia
4. Obesity
5. Diet
6. Physical activity
7. Stress
8. Family History
9. Age
10. 10)Habits
Coming to analysis of socio economic profile rather than as a traditional risk
factor we had intended to see the dispersion of various economic strata visiting our
hospital. Coming to the analysis of socioeconomic profile, most of the population that is
around 72% of them were in II, III, IV economic strata among cases as per modified
prasads classification. Among controls 41% were in these classes.
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In controls alone : The dispersion and percentages of various data in cases are given as
below, Tab.10-23
Age Frequency Percent
18-45 16 59.3
46-80 11 40.7
Total 27 100.0
Sex Frequency Percent
Male 16 59.3
Female 11 40.7
Total 27 100.0
Hscrp Frequency Percent
No 20 74.1
Yes 7 25.9
Total 27 100.0
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HSP 60 Frequency Percent
No 19 70.4
Yes 8 29.6
Total 27 100.0
Socio Economic profile Frequency Percent
I 16 59.3
II 7 25.9
III 3 11.1
IV 1 3.7
Total 27 100.0
Physical activity Frequency Percent
Inactive 21 77.8
Minimally Inactive 5 18.5
Hepa active 1 3.7
Total 27 100.0
Diet Frequency Percent
As per RDA 12 44.4
More than RDA 11 40.7
Less than RDA 4 14.8
Total 27 100.0
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T2DM Frequency Percent
No 22 81.5
Yes 5 18.5
Total 27 100.0
SHTN Frequency Percent
No 25 92.6
Yes 2 7.4
Total 27 100.0
Dyslipidemia Frequency Percent
No 4 14.8
Yes 23 85.2
Total 27 100.0
Habits Frequency Percent
No 18 66.7
Smoker 2 7.4
Alcoholic 5 18.5
Both 2 7.4
Total 27 100.0
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Family history Frequency Percent
No 21 77.8
Yes 6 22.2
Total 27 100.0
Stress Frequency Percent
No 12 44.4
Mild 12 44.4
Moderate 2 7.4
Severe 1 3.7
Total 27 100.0
Obesity Frequency Percent
No 9 33.3
Over weight 16 59.3
Obesity 2 7.4
Total 27 100.0
In cases alone Tab.24-35
Age Frequency Percent
18-45 8 24.2
46-80 25 75.8
Total 33 100.0
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Sex Frequency Percent
Male 26 78.8
Female 7 21.2
Total 33 10.0
Physical activity Frequency Percent
0 1 3.0
Inactive 26 78.8
Minimally Inactive 6 18.2
Total 33 100.0
Hscrp Frequency Percent
No 15 45.5
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Yes 18 54.5
Total 33 100.0
Diet Frequency Percent
As per RDA 12 36.4
More than RDA 15 45.5
Less than RDA 6 18.2
Total 33 100.0
T2DM Frequency Percent
No 14 42.4
Yes 19 57.6
Total 33 100.0
Hyper Tension Frequency Percent
No 18 70.4
Yes 15 29.6
Total 33 100.0
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Dyslipidemia Frequency Percent
Yes 29 87.9
Not known 4 12.1
Total 33 100.0
Habits Frequency Percent
No 13 39.4
Smoker 8 24.2
Alcoholic 2 6.1
Both 10 30.3
Total 33 100.0
Family history Frequency Percent
No 19 57.6
Yes 14 42.4
Total 33 100.0
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Stress Frequency Percent
No 5 15.2
Mild 10 30.3
Moderate 11 33.3
Severe 4 12.1
Not known 3 9.1
Total 33 100.0
Obesity Frequency Percent
No 5 15.2
Over weight 16 48.5
Obesity 12 36.4
Total 33 100.0
Among cases with STEMI the following is the incidence of various mi, with
anterior wall mi being highest in occurrence with 60.6% and clinically Killip class I/II
were 42.2 and 45.5 %. Tab.25-26
ACS Frequency Percent
AWMI 20 60.6
AW+LWMI 1 3.0
IWMI 10 30.3
PWMI 1 3.0
IW+PWMI 1 3.0
Total 33 100.0
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Killip Class Frequency Percent
CLASS I 14 42.4
CLASS II 15 45.5
CLASS III 2 6.1
CLASS IV 2 6.1
Total 33 100.0
Comparision between hsCRP and type of MI Tab.27
Hscrp
TotalNo Yes P value
ACS AWMI No 10 10 20 0.533
% 66.7% 55.6% 60.6%
AW+LWMI No 0 1 1
% .0% 5.6% 3.0%
IWMI No 4 6 10
% 26.7% 33.3% 30.3%
PWMI No 1 0 1
% 6.7% .0% 3.0%
IW+PWMI No 0 1 1
% .0% 5.6% 3.0%
Total No 15 18 33
% 100.0% 100.0% 100.0%
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Comparision between type of wall involvement and HSP 60 values Tab.28
Hsp60
TotalNo Yes P value
ACS AWMI No 12 8 20 0.469
% 66.7% 53.3% 60.6%
AW+LWMI No 1 0 1
% 5.6% .0% 3.0%
IWMI No 5 5 10
% 27.8% 33.3% 30.3%
PWMI No 0 1 1
% .0% 6.7% 3.0%
IW+PWMI No 0 1 1
% .0% 6.7% 3.0%
Total No 18 15 33
% 100.0% 100.0% 100.0%
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Comparison between HSCRP & Killip class in cases alone Tab.29
Hscrp
TotalNo Yes P value
Kilip class CLASS I No 9 5 14 0.244
% 60.0% 27.8% 42.4%
CLASS II No 4 11 15
% 26.7% 61.1% 45.5%
CLASS III No 1 1 2
% 6.7% 5.6% 6.1%
CLASS IV No 1 1 2
% 6.7% 5.6% 6.1%
Total No 15 18 33
% 100.0% 100.0% 100.0%
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Comparison between HSP60 & Killip class in cases alone Tab.30
Hsp60
TotalNo Yes P value
Kilip class CLASS I No 8 6 14 0.451
% 44.4% 40.0% 42.4%
CLASS II No 9 6 15
% 50.0% 40.0% 45.5%
CLASS III No 0 2 2
% .0% 13.3% 6.1%
CLASS IV No 1 1 2
% 5.6% 6.7% 6.1%
Total No 18 15 33
% 100.0% 100.0% 100.0%
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The levels of HSCRP were positive  in 54.5% of cases and 25.9% of controls.
While  the levels were absent or not detectable that is value was less than 0.5 mg/dl (as
per our lab reference) in 74.1% of controls and45.5% of cases. When assessed for
statistical significance, it was found that the p value for HSCRP was  found to be <0.05
with a value of 0.023. It signifies that the level of HSCRP was statistically significant in
cases. The ODDs ratio was 3.43, with CI not spanning much, indicating its significance
on outcome of acute coronary syndrome. The levels of HSP60 in the cases and controls
were significant (.2mg/ml) in 29.6% and 29.6% respectively. When evaluated for
statistical significance, there was found to be no statistical significant p value (0.162).
However, the ODDs ratio is 1.54 indicating the possibility or ODDs of relation with
exposure  to infection having relation with acute coronary syndrome outcome. The CI is
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spanned between 1.478 and 0.173 with wide range signifying losses, possibility of
relation or risk of infection causing ACS, 30.3% of cases had both positive values of
HSP60 and hSCRP while 11.1% had both positive values. The p value for both being
0.068. However among the four cases who died three had both positive values for
hSCRP and HSP60. Tab.31
Cases or Controls
TotalCases Controls P value
HSCRP No No 15 20 35 0.023
% 45.5% 74.1% 58.3%
Yes No 18 7 25
% 54.5% 25.9% 41.7%
Total No 33 27 60
% 100.0% 100.0% 100.0%
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Tab.32
Cases or Controls
TotalCases Controls P value
HSP 60 No No 18 19 37 0.162
% 54.5% 70.4% 61.7%
Yes No 15 8 23
% 45.5% 29.6% 38.3%
Total No 33 27 60
% 100.0% 100.0% 100.0%
20 of 33 patients had anterior wall MI and 10 of 33 patients had inferior wall MI
and one had lateral wall and two had posterior wall MI along with inferior wall MI. Of
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these 10 who had inferior wall MI 4 had both hsCRP and HSP 60 positive while among
20 anterior wall MI 5 had both positive.HSP 60 was positive in 8 of 20 anterior wall MI
and 5 of 10 inferior wall MI. Level of inflammation was also relatively more often seen in
inferior wall MI patients. Of these 12 had complications secondary to ACS, most
common being MR and followed by cardiogenic shock and VT,VF.MR is commonly seen
associated with inferior wall MI.
Of 33 patients 7 have been thrombolysed in hospital and 4 have been
thrombolysed outside with one failed lysis. Among these patients who have been
thrombolysed outside and referred for complications had elevated hsCRP compared to in
hospital thrombolysed patients.
Of 33 patients 22 underwent PCI, where 7 underwent primary PCI with drug
eluting stent placement. Among these two had restenoses of stent within a duration of a
week and both these patients are associated with significantly elevated values of hsCRP
and HSP 60.Among 4 cases which expired 3 of them had both hsCRP and HSP 60 values
elevation, of them one had hepatitis B infection. However 2 patients had lower respiratory
tract infection during hospital stay and they did not have much elevation of HSP 60
compared to hepatitis B patient suggesting role of HSP 60 in chronic infection. This
needs further evaluation.
Of the 22 patients who underwent PCI 9 had triple vessel disease. Among the 9
patients 3 had both elevated hsCRP and HSP 60 while 2 had hsCRP alone elevated.
Patients with single and double vessel disease were 11 and among them 4 had elevation
of both hsCRP and HSP 60 while HSP 60 and hsCRP were individually elevated in 2
each of these patients.
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Among these patients ,3 got discharged against medical advise even prior to
admission while 4 were dead during hospital stay 3 due to cardiac arrest secondary to
VT,VF and one due to restenoses of stent.The remaining 26 patients 13 were under follow
up and the other 13 are yet to come for follow up.
Comparisons of all risk factors with HSCRP :
For traditional risk factors the statistical analysis is as follows,
Tab.33
TD2M
Hscrp
Total
No Yes P value
No
Category
With ACS &
Killip Class
Count 9 5 14 0.318
% within Hscrp 34.6% 50.0% 38.9%
Without ACS&
Killip Class
Count 17 5 22
% within Hscrp 65.4% 50.0% 61.1%
Total
Count 26 10 36
% within Hscrp 100.0% 100.0% 100.0%
Yes
Category
With ACS &
Killip Class
Count 6 13 19 0.255
% within Hscrp 66.7% 86.7% 79.2%
Without ACS &
Killip Class
Count 3 2 5
% within Hscrp 33.3% 13.3% 20.8%
Total Count 9 15 24
% within Hscrp 100.0% 100.0% 100.0%
The age old known risk factors as type 2 diabetes mellitus is present in 57.6% of
cases and 18.5% of controls. Diabetics seems to have statistical significant influence on
the level of hsCRP ,with a p value of 0.002.However like habits, diabetes when compared
in both case and controls to the level of inflammation donot seem to have a statistical
significance.
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Tab.34
Physical activity
Hscrp
Total
No Yes P value
0
Category With ACS &Killip Class
Count 1 1
% within Hscrp 100.0% 100.0%
Total
Count 1 1
% within Hscrp 100.0% 100.0%
Inactive
Category
With ACS &
Killip Class
Count 14 18 32 0.034
% within Hscrp 42.4% 72.0% 55.2%
Without ACS
& Killip Class
Count 19 7 26
% within Hscrp 57.6% 28.0% 44.8%
Total
Count 33 25 58
% within Hscrp 100.0% 100.0% 100.0%
Hepa active
Category Without ACS& Killip Class
Count 1 1
% within Hscrp 100.0% 100.0%
Total
Count 1 1
% within Hscrp 100.0% 100.0%
Physical activity as per IPAQ question questionnaire  analysis was done and
patients with physical inactivity had more incidences of ACS and relation with hSCRP
was statistically significant with P value of 0.034.
More calorie diet as per 24 hour diet recall and following RDA guidelines for
Indian population gave an outcome of 55% of cases having such diet. On comparing with
hsCRP it does not have a statistical significance in patients and controls with elevated
hsCRP while there was surprisingly relation between low calorie or normal diet in cases
and controls with elevation of hsCRP.
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Tab.35
Diet
Hscrp
Total
No Yes P value
As per RDA
Category
With ACS &
Killip Class
Count 7 11 18 0.037
% within Hscrp 36.8% 73.3% 52.9%
Without ACS &
Killip Class
Count 12 4 16
% within Hscrp 63.2% 26.7% 47.1%
Total
Count 19 15 34
% within Hscrp 100.0% 100.0% 100.0%
More than
RDA
Category
With ACS &
Killip Class
Count 8 7 15 0.277
% within Hscrp 50.0% 70.0% 57.7%
Without ACS &
Killip Class
Count 8 3 11
% within Hscrp 50.0% 30.0% 42.3%
Total
Count 16 10 26
% within Hscrp 100.0% 100.0% 100.0%
The influence of systemic hypertension neither seem to have statistical
significance in cases or controls with hsCRP and overall together in entire study
population.
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Tab.36
SHTN
Hscrp
Total
No Yes P value
No
Category
With ACS &
Killip Class
Count 8 8 16 0.085
% within Hscrp 29.6% 57.1% 39.0%
Without ACS &
Killip Class
Count 19 6 25
% within Hscrp 70.4% 42.9% 61.0%
Total
Count 27 14 41
% within Hscrp 100.0% 100.0% 100.0%
Yes
Category
With ACS &
Killip Class
Count 7 10 17 0.678
% within Hscrp 87.5% 90.9% 89.5%
Without ACS &
Killip Class
Count 1 1 2
% within Hscrp 12.5% 9.1% 10.5%
Total
Count 8 11 19
% within Hscrp 100.0% 100.0% 100.0%
Dyslipidemia ,seem to have a significant statistical significance in cases and
influence to level of inflammation in body with a p value of 0.017.
In overall study population too,the level of dyslipidemia seen in 87.9% cases and
85.2% of controls seem to have a statistical significant p value of 0.015.
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Tab.37
Dyslipidemia
Hscrp
Total
No Yes P value
No
Category Without ACS& Killip Class
Count 2 2 4
% within Hscrp 100.0% 100.0% 100.0%
Total
Count 2 2 4
% within Hscrp 100.0% 100.0% 100.0%
Yes
Category
With ACS &
Killip Class
Count 13 16 29 0.015
% within Hscrp 41.9% 76.2% 55.8%
Without ACS
& Killip Class
Count 18 5 23
% within Hscrp 58.1% 23.8% 44.2%
Total
Count 31 21 52
% within Hscrp 100.0% 100.0% 100.0%
2
Category With ACS &Killip Class
Count 2 2 4
% within Hscrp 100.0% 100.0% 100.0%
Total
Count 2 2 4
% within Hscrp 100.0% 100.0% 100.0%
Presence of habits seem to have statistical significance in cases with relation to hs
CRP where p value is 0.015.Habits include smoking, alcohol intake and both. Among
cases both smoking and alcoholic patients are 33.3% and alcoholic and smokers alone are
6.1% and 24.2% respectively. Among controls, more percentage that is 66.7% donot have
any habits. However ,seen overall, habits donot seem to influence the level of hsCRP in
the cases and controls.
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Tab.38
Habits
Hscrp
Total
No Yes P value
No
Category
With ACS &
Killip Class
Count 5 8 13 0.065
% within Hscrp 27.8% 61.5% 41.9%
Without ACS &
Killip Class
Count 13 5 18
% within Hscrp 72.2% 38.5% 58.1%
Total
Count 18 13 31
% within Hscrp 100.0% 100.0% 100.0%
Smoker
Category
With ACS &
Killip Class
Count 3 5 8 0.667
% within Hscrp 75.0% 83.3% 80.0%
Without ACS &
Killip Class
Count 1 1 2
% within Hscrp 25.0% 16.7% 20.0%
Total
Count 4 6 10
% within Hscrp 100.0% 100.0% 100.0%
Alcoholic
Category
With ACS &
Killip Class
Count 2 0 2 0.714
% within Hscrp 33.3% .0% 28.6%
Without ACS &
Killip Class
Count 4 1 5
% within Hscrp 66.7% 100.0% 71.4%
Total
Count 6 1 7
% within Hscrp 100.0% 100.0% 100.0%
Both
Category
With ACS &
Killip Class
Count 5 5 10 0.318
% within Hscrp 71.4% 100.0% 83.3%
Without ACS &
Killip Class
Count 2 0 2
% within Hscrp 28.6% .0% 16.7%
Total
Count 7 5 12
% within Hscrp 100.0% 100.0% 100.0%
In case of family history too there was statistical significance in population
without family history of acute coronary syndrome in relation to hsCRP values with a
significant p value of 0.013.Overall 14 cases had family history of CAD and 6 controls
had family history of coronary artery disease.
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Tab.39
Family History
Hscrp
Total
No Yes P value
No
Category
With ACS &
Killip Class
Count 8 11 19 0.013
% within Hscrp 32.0% 73.3% 47.5%
Without ACS &
Killip Class
Count 17 4 21
% within Hscrp 68.0% 26.7% 52.5%
Total
Count 25 15 40
% within Hscrp 100.0% 100.0% 100.0%
Yes
Category
With ACS &
Killip Class
Count 7 7 14 0.686
% within Hscrp 70.0% 70.0% 70.0%
Without ACS &
Killip Class
Count 3 3 6
% within Hscrp 30.0% 30.0% 30.0%
Total
Count 10 10 20
% within Hscrp 100.0% 100.0% 100.0%
Stress levels as assessed by Goldberg Depression scale revealed only 75% of the
patients had no stress while rest had stress in various categories ranging from mild,
moderate to severe. However due to acute presentation and death within few hours of
admission among 3 cases, stress levels with questionnaire form could not be assessed.
Among controls without stress were almost 40%. However, no statistical significance was
found between various gradings of stress and hsCRP levels.
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Tab.40
Stress
Hscrp
Total
No Yes P value
No
Category
With ACS &
Killip Class
Count 3 2 5 0.330
% within Hscrp 23.1% 50.0% 29.4%
Without ACS
& Killip
Class
Count 10 2 12
% within Hscrp 76.9% 50.0% 70.6%
Total
Count 13 4 17
% within Hscrp 100.0% 100.0% 100.0%
Mild
Category
With ACS &
Killip Class
Count 4 6 10 0.335
% within Hscrp 36.4% 54.5% 45.5%
Without ACS
& Killip
Class
Count 7 5 12
% within Hscrp 63.6% 45.5% 54.5%
Total
Count 11 11 22
% within Hscrp 100.0% 100.0% 100.0%
Moderate
Category
With ACS &
Killip Class
Count 5 6 11 0.269
% within Hscrp 71.4% 100.0% 84.6%
Without ACS
& Killip
Class
Count 2 0 2
% within Hscrp 28.6% .0% 15.4%
Total
Count 7 6 13
% within Hscrp 100.0% 100.0% 100.0%
Severe
Category
With ACS &
Killip Class
Count 1 3 4 0.400
% within Hscrp 50.0% 100.0% 80.0%
Without ACS
& Killip
Class
Count 1 0 1
% within Hscrp 50.0% .0% 20.0%
Total
Count 2 3 5
% within Hscrp 100.0% 100.0% 100.0%
Not
known
Category
With ACS &
Killip Class
Count 2 1 3
% within Hscrp 100.0% 100.0% 100.0%
Total Count 2 1 3
% within Hscrp 100.0% 100.0% 100.0%
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Obesity as graded by WHO criteria showed 84.8% of cases in overweight and
obesity cader and 66.66% of controls with obesity. Similarly they also seem to influence
the hsCRP values. Tab.41
Obesity
Hscrp
Total
No Yes P value
No
Category
With ACS &
Killip Class
Count 1 4 5 0.023
% within Hscrp 11.1% 80.0% 35.7%
Without ACS &
Killip Class
Count 8 1 9
% within Hscrp 88.9% 20.0% 64.3%
Total
Count 9 5 14
% within Hscrp 100.0% 100.0% 100.0%
Over
weight
Category
With ACS &
Killip Class
Count 14 14 28 0.210
% within Hscrp 53.8% 70.0% 60.9%
Without ACS &
Killip Class
Count 12 6 18
% within Hscrp 46.2% 30.0% 39.1%
Total
Count 26 20 46
% within Hscrp 100.0% 100.0% 100.0%
Tab.42
Age
Hscrp
Total
No Yes P value
18-45
Category
With ACS &
Killip Class
Count 5 3 8 0.302
% within Hscrp 27.8% 50.0% 33.3%
Without ACS &
Killip Class
Count 13 3 16
% within Hscrp 72.2% 50.0% 66.7%
Total
Count 18 6 24
% within Hscrp 100.0% 100.0% 100.0%
46-80
Category
With ACS &
Killip Class
Count 10 15 25 0.172
% within Hscrp 58.8% 78.9% 69.4%
Without ACS &
Killip Class
Count 7 4 11
% within Hscrp 41.2% 21.1% 30.6%
Total
Count 17 19 36
% within Hscrp 100.0% 100.0% 100.0%
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Regression analysis for hsCRP AS DEPENDENT VARIABLE
Model Summaryb
Model R R Square
Adjusted R
Square
Std. Error of
the Estimate
Overall
significance
1 .756a .571 .237 .44155 0.141
a. Predictors: (Constant), Killip class, Physical activity,
Diet, age, ACS, Obesity, TD2M, Socio economic profile,
Family History, SHTN, Stress, sex, Habits, Dyslipidemia
b. Dependent Variable: Hscrp
Tab.43
Coefficientsa
Model
Unstandardized
Coefficients
Standardized
Coefficients T Sig.
B Std. Error Beta
1 (Constant) 1.699 .730 2.329 .032
Age .323 .246 .278 1.311 .206
Sex -.364 .277 -.299 -1.315 .205
Socio economic profile .132 .096 .277 1.376 .186
Physical activity -.584 .257 -.510 -2.269 .036
Diet -.146 .149 -.210 -.978 .341
TD2M .345 .180 .343 1.917 .071
SHTN -.165 .213 -.165 -.774 .449
Dyslipidemia -.823 .443 -.539 -1.857 .080
Habits -.113 .088 -.287 -1.279 .217
Family History -.291 .196 -.289 -1.487 .154
Stress -.035 .122 -.080 -.287 .777
Obesity -.246 .135 -.339 -1.825 .085
ACS -.018 .096 -.040 -.184 .856
.364 .156 .598 2.329 .032
a. Dependent Variable: Hscrp
82
83
COMPARISION OF HSP 60 WITH TRADITIONAL RISK FACTORS
Tab.44
Physical activity
Hsp60
Total
No Yes P value
0
Category With ACS & Killip class
Count 1 1
% within
Hsp60 100.0% 100.0%
Total
Count 1 1
% within
Hsp60 100.0% 100.0%
Inactive
Category
With ACS & Killip class
Count 17 15 32 0.164
% within
Hsp60 48.6% 65.2% 55.2%
Without ACS & killip class
Count 18 8 26
% within
Hsp60 51.4% 34.8% 44.8%
Total
Count 35 23 58
% within
Hsp60 100.0% 100.0% 100.0%
Hepa
active
Category Without ACS & killip class
Count 1 1
% within
Hsp60 100.0% 100.0%
Total
Count 1 1
% within
Hsp60 100.0% 100.0%
This explains the distribution of physical activity in cases and controls and their
relation with HSP 60 values. Most of the population in the study seem to be physically
inactive.
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Tab.45
Diet
Hsp60
Total
No Yes P value
As per
RDA
Category
With ACS & Killip class
Count 11 7 18 0.459
% within
Hsp60 50.0% 58.3% 52.9%
Without ACS & killip class
Count 11 5 16
% within
Hsp60 50.0% 41.7% 47.1%
Total
Count 22 12 34
% within
Hsp60 100.0% 100.0% 100.0%
More than
RDA
Category
With ACS & Killip class
Count 7 8 15 0.178
% within
Hsp60 46.7% 72.7% 57.7%
Without ACS & kilip class
Count 8 3 11
% within
Hsp60 53.3% 27.3% 42.3%
Total
Count 15 11 26
% within
Hsp60 100.0% 100.0% 100.0%
This table highlights the fact that most of the population are taking food above
RDA guidelines and their distribution on comparision with HSP 60 VALUES.HSP 60
does not seem to have statistical significance with diet.
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Tab.46
TD2M
Hsp60
Total
No Yes P value
No
Category
With ACS & Killip class Count 6 8 14 0.075
% within
Hsp60 27.3% 57.1% 38.9%
Without ACS & killip class Count 16 6 22
% within
Hsp60 72.7% 42.9% 61.1%
Total
Count 22 14 36
% within
Hsp60 100.0% 100.0% 100.0%
Yes
Category
With ACS & Killip class Count 12 7 19 0.640
% within
Hsp60 80.0% 77.8% 79.2%
Without ACS & killip class Count 3 2 5
% within
Hsp60 20.0% 22.2% 20.8%
Total
Count 15 9 24
% within
Hsp60 100.0% 100.0% 100.0%
This table highlights the fact that absence of diabetes has statistical significance in
the levels of HSP60 in both cases and controls.
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Tab.47
SHTN
Hsp60
Total
No Yes P value
No
Category
With ACS & Killip class
Count 8 8 16 0.137
% within
Hsp60 30.8% 53.3% 39.0%
Without ACS & killip class
Count 18 7 25
% within
Hsp60 69.2% 46.7% 61.0%
Total
Count 26 15 41
% within
Hsp60 100.0% 100.0% 100.0%
Yes
Category
With ACS & Killip class
Count 10 7 17 0.678
% within
Hsp60 90.9% 87.5% 89.5%
Without ACS & killip class
Count 1 1 2
% within
Hsp60 9.1% 12.5% 10.5%
Total
Count 11 8 19
% within
Hsp60 100.0% 100.0% 100.0%
This table explains that either absence or presence of hypertension has no
influence on HSP 60 values
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Tab.48
Dyslipidemia
Hsp60
Total
No Yes P value
No
Category Without ACS & kilip class
Count 3 1 4
% within
Hsp60 100.0% 100.0% 100.0%
Total
Count 3 1 4
% within
Hsp60 100.0% 100.0% 100.0%
Yes
Category
With ACS & Killip class
Count 15 14 29 0.154
% within
Hsp60 48.4% 66.7% 55.8%
Without ACS & killip class
Count 16 7 23
% within
Hsp60 51.6% 33.3% 44.2%
Total
Count 31 21 52
% within
Hsp60 100.0% 100.0% 100.0%
2
Category With ACS & Killip class
Count 3 1 4
% within
Hsp60 100.0% 100.0% 100.0%
Total
Count 3 1 4
% within
Hsp60 100.0% 100.0% 100.0%
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Tab.49
Habits
Hsp60
Total
No Yes P value
No
Category
With ACS & Killip class
Count 8 5 13 0.534
% within
Hsp60 40.0% 45.5% 41.9%
Without ACS & killip class
Count 12 6 18
% within
Hsp60 60.0% 54.5% 58.1%
Total
Count 20 11 31
% within
Hsp60 100.0% 100.0% 100.0%
Smoker
Category
With ACS & Killip class
Count 5 3 8 0.667
% within
Hsp60 83.3% 75.0% 80.0%
Without ACS & kilip class
Count 1 1 2
% within
Hsp60 16.7% 25.0% 20.0%
Total
Count 6 4 10
% within
Hsp60 100.0% 100.0% 100.0%
Alcoholic
Category
With ACS & Killip class
Count 0 2 2 0.143
% within
Hsp60 .0% 66.7% 28.6%
Without ACS & killip class
Count 4 1 5
% within
Hsp60 100.0% 33.3% 71.4%
Total
Count 4 3 7
% within
Hsp60 100.0% 100.0% 100.0%
Both
Category
With ACS & Killip class
Count 5 5 10 0.318
% within
Hsp60 71.4% 100.0% 83.3%
Without ACS & killip class
Count 2 0 2
% within
Hsp60 28.6% .0% 16.7%
Total
Count 7 5 12
% within
Hsp60 100.0% 100.0% 100.0%
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Tab.50
Family History
Hsp60
Total
No Yes P value
No
Category
With ACS & Killip class
Count 9 10 19 0.273
% within
Hsp60 40.9% 55.6% 47.5%
Without ACS & killip class
Count 13 8 21
% within
Hsp60 59.1% 44.4% 52.5%
Total
Count 22 18 40
% within
Hsp60 100.0% 100.0% 100.0%
Yes
Category
With ACS & Killip class
Count 9 5 14 0.129
% within
Hsp60 60.0% 100.0% 70.0%
Without ACS & killip class
Count 6 0 6
% within
Hsp60 40.0% .0% 30.0%
Total
Count 15 5 20
% within
Hsp60 100.0% 100.0% 100.0%
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Tab.51 & 52
Stress
Hsp60
Total
No Yes P value
No
Category
With ACS & Killip class
Count 3 2 5 0.472
% within
Hsp60
25.0
% 40.0% 29.4%
Without ACS & killip class
Count 9 3 12
% within
Hsp60
75.0
% 60.0% 70.6%
Total
Count 12 5 17
% within
Hsp60
100.0
% 100.0% 100.0%
Mild
Category
With ACS & Killip class
Count 6 4 10 0.639
% within
Hsp60
46.2
% 44.4% 45.5%
Without ACS & killip class
Count 7 5 12
% within
Hsp60
53.8
% 55.6% 54.5%
Total
Count 13 9 22
% within
Hsp60
100.0
% 100.0% 100.0%
Moderate
Category
With ACS & Killip class
Count 4 7 11 0.192
% within
Hsp60
66.7
% 100.0% 84.6%
Without ACS & killip class
Count 2 0 2
% within
Hsp60
33.3
% .0% 15.4%
Total
Count 6 7 13
% within
Hsp60
100.0
% 100.0% 100.0%
Severe
Category
With ACS & Killip class
Count 2 2 4 0.600
% within
Hsp60
66.7
% 100.0% 80.0%
Without ACS & killip class
Count 1 0 1
% within
Hsp60
33.3
% .0% 20.0%
Total
Count 3 2 5
% within
Hsp60
100.0
% 100.0% 100.0%
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Not
known
Category With ACS & Killip class
Count 3 3
% within
Hsp60
100.0
% 100.0%
Total
Count 3 3
% within
Hsp60
100.0
% 100.0%
Obesity
Hsp60
Total
No Yes P value
No
Category
With ACS & Killip class
Count 2 3 5 0.500
% within
Hsp60 28.6% 42.9% 35.7%
Without ACS & killip class
Count 5 4 9
% within
Hsp60 71.4% 57.1% 64.3%
Total
Count 7 7 14
% within
Hsp60 100.0% 100.0% 100.0%
Over
weight
Category
With ACS & Killip class
Count 16 12 28 0.132
% within
Hsp60 53.3% 75.0% 60.9%
Without ACS & killip class
Count 14 4 18
% within
Hsp60 46.7% 25.0% 39.1%
Total
Count 30 16 46
% within
Hsp60 100.0% 100.0% 100.0%
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Tab.53
Age
Hsp60
Total
No Yes P value
18-45
Category
With ACS & Killip class
Count 4 4 8 0.134
% within
Hsp60 23.5% 57.1% 33.3%
Without ACS & killip class
Count 13 3 16
% within
Hsp60 76.5% 42.9% 66.7%
Total
Count 17 7 24
% within
Hsp60 100.0% 100.0% 100.0%
46-80
Category
With ACS & Killip class
Count 14 11 25 0.609
% within
Hsp60 70.0% 68.8% 69.4%
Without ACS & killip class
Count 6 5 11
% within
Hsp60 30.0% 31.2% 30.6%
Total
Count 20 16 36
% within
Hsp60 100.0% 100.0% 100.0%
Regression analysis for hsp 60 in cases alone :
Coming to HSP 60,none of the traditional risk factors seem to have any much
influence in the cases .On regression analysis,the adjusted R square values for the HSP 60
is -0.201,with a significance of 0.818,which is not statistically significant.This indicates
that HSP 60 is influenced upto 20% by the traditional risk factors in cases.
Model Summaryb
Model R R Square Adjusted RSquare
Std. Error of
the Estimate Sig
1 .570a .324 -.201 .55412 0.818
a. Predictors: (Constant), Killip class, Physical activity,
Diet, age, ACS, Obesity, TD2M, Socio economic profile,
Family History, SHTN, Stress, sex, Habits, Dyslipidemia
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Coefficientsa Tab.54
Model
Unstandardized
Coefficients
Standardized
Coefficients T Sig.
B Std. Error Beta
1 (Constant) 1.316 .916 1.437 .168
Age .171 .309 .147 .554 .587
Sex .160 .348 .131 .461 .651
Socio economic profile -.046 .120 -.097 -.385 .705
Physical activity -.244 .323 -.213 -.755 .460
Diet .127 .188 .183 .678 .506
TD2M -.221 .226 -.220 -.979 .340
SHTN -.010 .267 -.010 -.038 .970
Dyslipidemia -.644 .556 -.422 -1.159 .262
Habits .089 .111 .226 .805 .432
Family History -.309 .246 -.307 -1.260 .224
Stress .076 .153 .175 .500 .623
Obesity -.237 .169 -.326 -1.399 .179
ACS .007 .120 .017 .062 .951
Killip class .155 .196 .255 .791 .439
a. Dependent Variable: Hsp60
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The analysis of other risk factors like gender, waist circumference  and waist hip
ratio due to limitation of data collection in stipulated time was not done. Waist hip ratio
was not  collected for the reason that most of the cases came with complication of acute
coronary syndrome.  These  measurements were not collected at time of  discharge in the
cases who got successfully treated and discharged, as the  admission waist and hip ratio
differed from the discharge ones, due to loss of free fluid  due to administration of
diuretics in the patients who presented with volume overload and patient had some
amount of weight loss during hospital stay due to diseases state and also due to low fat,
low calorie diet.
In case of  gender, as the samples had to be collected in a stipulated running time
of the wells for HSP 60 in a duration of 60 days ,this parameter was not been analyzed in
a statistically significant numbers. As the selection of cases never had inclusion of gender
as priority. In our study we had total of 21.2% of females in both cases and 78.8% of
males in cases .In controls, however,the ratio varied, with 40.7% being females and
59.3% being males. As the major aim of  the study is to analyze level of infection and
inflammation in acute coronary syndrome patients. We have not analyzed the data in the
cases on the base of gender due to relatively low percentage of female population.
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DISCUSSION
Heat shock protein 60 is a disease associated molecular pattern which is released
under hemodynamic stress conditions from the mitochondria and cytoplasm of the
vascular endothelial cells(56). It has various levels of distribution in the cell, in
endoplasmic reticulum, mitochondria, cell surface and cytoplasm(66). HSP 60 belonging to
the family of chaperonins, is a group of autoantigens based on the fact that it is a highly
preserved molecule in eukaryotes and prokaryotes. Our study highlighted this molecular
mimicry concept of HSP 60, where exposure to various bacterial and viral HSP 60 in a
person’s lifetime stimulates production of CD4 + T cells and antibodies against these
molecules, which have the potential to act on human HSP 60 released under
hemodynamic stress into circulation and initiate or accelerate inflammation in the
vascular tree and precipitate major vascular events like acute coronary syndrome. It was
found in a study by, M. Knoflach, S.Kiechl, M.Kind et al that in the initial phases of
atherosclerotic process,   CD4 + T cells are found in large numbers which mount reaction
against HSP 60 and accelerate the process of atherosclerosis(67). This count of CD4 + T
cells is more in young population, hence the process of atherosclerosis mediated by HSP
60 can start in a very young age as evident by carotid intimal lesions. The analysis of
ARMY study by M. Knoflach et al highlighted HSP 60 as one of the risk factor for
atherosclerosis at a younger age(67).
In our study the levels of HSP 60 were found to be elevated in acute coronary
syndrome patients as compared to controls with a significant ODDS ratio and confidence
interval(CI). However the distribution of seropositivity of  HSP 60 evaluated in our study
had no statistically significant p value between case and controls. This indicates wide
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spread of either infection associated or stress associated circulation of  heat shock protein
60 in the body. Also suggests larger population evaluation of HSP 60 values.
The control arm in our study was healthy population with no evidence of coronary
artery disease as per ECG. However the level of atherosclerosis in them as seen in other
studies through carotid intimal thickening has not been evaluated due to financial
constrains. The control arm had larger incidence of overweight population, which can act
as hemodynamic stressor and can cause release of HSP 60 into circulation. The role of
antibodies to HSP 60 has to be highlighted here, which are a more direct marker of
atherosclerosis in human body(66).
Our study showed that subjects with inferior wall MI had elevated levels of HSP
60 compared to anterior wall MI and had more complications. These findings support the
use of HSP 60 as a prognostic marker in future.
A study by Zang X et al, showed increased risk of CAD in patients with elevated
HSP 60 levels and much more risk when patients had elevated antibodies to HSP 60
levels(54).
The value of HSP 60 as a prognostic marker was supported by a study in
emergency department by , DH Birnie, LE Vickers et al where they found that patient
visiting their hospital with chest pain had a poor prognosis on follow up a year later when
they had elevated HSP 60 levels at admission(68).
In our study, the role of inflammation in acute coronary syndrome has been
highlighted for the fact that our cases had statistically significant elevated levels of HSP
60, compared to control group. In our case control study, we evaluated the role of
infection in causing acute coronary syndrome through activation of autoimmune
pathways where, the level of infection in the body was measured indirectly by assessing
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HSP 60 and the inflammatory pathway activation responsible for ACS by measuring
circulating levels of HSP 60
Based on this concept, we highlighted the role of inflammation mediated
activation of plaque rupture causing ACS. The role of infection in activating or
progressing inflammation is evident in our study. As our cases who had complications (9
patients) and who had death during hospital stay (4 patients) had both elevated levels of
hsCRP and HSP 60
Previous Studies:
A study by Biasucci LM et al, proved that unrelated to even hsCRP, elevated
levels of Chlamydial HSP 60 was a marker for ACS which has both good sensitivity and
specificity. In this study HSP 60  and hsCRP were evaluated in 179 patients with unstable
angina and 40 patients with ACS against 30 control population(56).
A study by Zhang X et al in a group of 1003 CHD patients with controls found to
have increased risk of CHD in subjects with elevated levels of HSP 60 and antibodies to
HSP 60(54). The risk for ACS was elevated when traditional risk factors were also taken
into consideration in these subjects(54).
In our study we have proved that hsCRP is by itself an independent marker of the
level of atherosclerosis in human body associated to an extent with complication
secondary to ACS. hsCRP was significantly elevated in both our patients who had
restenosis of drug eluting stent within a week of procedure. The elevation of hsCRP was
independent of traditional risk factors. In our study, traditional risk factors like diabetes
mellitus, hypertension, physical inactivity and others influenced only 23% of the levels of
circulating hsCRP. Similarly even HSP 60 values were influenced a little by traditional
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risk factors. This highlights the concept that irrespective of traditional risk factors causing
inflammation, infection has a significant role in causing inflammation leading to ACS.
Our study does not deny the failure of previous antibiotic trials(47-49) where
antibiotics were used to treat ACS. As the organisms like Chlamydia pneumonia were
targeted in antibiotic trials (macrolide trials) where, the organism is not responsible for
the ongoing inflammation, rather it is a one hit hypotheses
The organisms effect the vascular and cause ongoing inflammation even at
clinically undetectable levels and once effected can cause ongoing proliferation of CD4 +
T cells and cause inflammatory mediated atherosclerosis(66). The activation of
inflammatory pathways increases the levels of pro inflammatory cytokines like IL-1P, IL-
12, IL-8, IL-18 other chemokines and interferon gamma can occur. On the other hand anti
inflammatory cytokines also are activated like IL-10 and tumor growth factor beta(25). The
balance between these pro inflammatory and anti inflammatory markers decide levle of
atherosclerosis in a human being.
From earlier studies it is evident that autoimmunity to heat shock protein
especially HSP 60 exists even in normally healthy individuals, as this will be released
into circulation under the  influence of any stress factor on vascular structures(66). This
explains our findings of seropositivity of HSP 60 even in our controls, as they had
traditional risk factors especially obesity was predominant in our population. It was
evident from earlier studies that central obesity will cause vascular stress and increased
inflammation, which explains the reason for prevalence of hsCRP elevation in our
controls(19). However, obesity was not statistically significant in influencing the presence
of both hsCRP and HSP 60 in both cases and controls. Diabetes had a statistically
significant role in influencing the levels of hsCRP  in our cases(19).
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Another major  factor associated with difference in levels of HSP 60 can be
genetic variability among cases. HSP 60 is presented to the CD4 + T cells through toll
like receptor, when single nucleotide polymorphism related to these receptors are present,
then HSP 60, even though patient is infected need not cause, inflammation(69,70). The role
of HSP 60 in activating β cells is yet to be established  and requires further studies(66).
Our major area of interest in this study is to establish the importance of
inflammation in atherosclerosis, which can be mediated through infection, as India has
rampant incidence of various infectious diseases.
Through this study we spotlight the importance of treatment modalities focusing on
inflammatory pathways in ACS.
The role of HSP vaccines, that cause tolerance to pathogenesis mediated through
HSP is established in phase I and II trials to treat melanomas (metastatic). Similar
principle can be used and animal studies examples can be utilized where vaccines against
HSP caused increased levels of protective cytokines levels like IL-10 and decreased the
plaque burden in the treated animals, for the treatment of human atherosclerosis mediated
diseases like acute coronary syndrome.(68)
One major limitation of these values and relation between infection and
atherogenesis is time. As infection exposure occurs at infancy and childhood, but the
clinical manifestations are mostly evident in adult stage.(70) It is the massive vascular
involvement or is it burden of pathogens or is it inflammation or existence  of risk factors,
which is responsible for adult manifestation of atherosclerosis has to be further evaluated.
This explains the role of traditional risk factors like oxidative stress, inflammation,
infection and lipoprotein a, in causing complex mechanism in atherogenesis and
cardiovascular diseases.
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LIMITATIONS:
1. Role of HSP 60 as marker of chronic infection requires further analysis in larger
group to evaluate for the difference between significant ODDS ratio and
statistically insignificant p value
2. Assessment of waist hip ratio in all the cases could not be done. This remains a
major limitation as in Indian population central obesity is one major cause for
inflammatory process in body
3. Few patients expired within few hours of admission ,for them stress scales could
not be evaluated
4. For all patients admitted coronary angiogram was not done to know the exact
coronary lesion
5. Few patients have been thrombolysed outside and for such patients samples have
been taken after thrombolyses which might affect levels of  hsCRP.
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SUGGESTIONS:
1. From the analysis of obtained data from our study we suggest further requirement
of analysis of role of infection in atherosclerosis process.This involves study of
various other molecules like IL-7,other heat shock proteins like HSP 70,HSP 65
and others.
2. Genetic variations or single nucleotide polymorphisms related to HSP60 as
polymorphisms of toll like receptors or IL-1 beta receptors can be analysed to
know the variation in HSP 60 levels in our population.
3. Targeted therapy involving immunisation against HSP 60 may decrease
atherosclerosis process as suggested by animal studies,hence this treatment
modality can be tried in humans too.
4. Larger population of STEMI cases has to be studied to know the variation of role
of infection and inflammation in various coronary artery lesions in a statistically
significant manner.
5. Potential involvement of infection as a novel risk factor in cases of young MI can
be evaluated based on these observations.This can partly explain the fact why
India is witnessing a higher incidence of young MI in recent days as India has
larger incidence of infectious diseases compared to developed nations.
6. Inflammation role in acute coronary syndrome can further be studied with
cytokines levels which are early markers of inflammation (IL-1,IL-6).
7. Further role of pathological and biochemical analysis of thrombus may give us a
better idea of level of inflammation and cholesterol content in the plaque which
can help us to tailor treatment to each individual.
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FUTURE PROSPECTIVES:
In future, genetic studies can be done on inflammation  as we succeeded in
achieving the positive relation between hs CRP and ACS .The CANTOS trial (The
CANAKINUMAB Anti inflammatory Thrombosis Outcomes Study) is designed to test
the hypotheses that IL-1beta inhibition will reduce major cardiovascular events in persons
with pre existing CAD.This is the first true test to support our hypothesis that interrupting
on inflammatory pathway involved in atherosclerosis will reduce cardiovascular
events.62.The Darapladib trial too proved the fact that anti-inflammatory drugs reduce the
atherosclerotic plaque burden.61.
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CONCLUSION:
It was proved through our study that elevated levels of HSP 60 has a role in acute
coronary syndrome and it can be used as a prognostic marker to know the outcome of the
patient especially when clubbed with hsCRP levels. However statistical  significance of
HSP 60 as a potential risk factor in acute coronary syndrome requires studies in all
clinical spectra of acute coronary syndrome. Role of inflammation was again proved in
our study with statistically significant levels of hsCRP in STEMI patients irrespective of
traditional risk factors. Hence role of genetics in relation to inflammation has to be
evaluated further to know how inflammatory response varies from individual to
individual.
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GLOSSARY
ACS – acute coronary syndrome
AWMI – anterior wall myocardial infarction
AW+LWMI – anterior wall and lateral wall myocardial infarction
CAD- coronary artery disease
CAG – coronary angiogram
ECG- electrocardiogram
HTN- hypertension
HSP- heat shock protein
HSP 60 heat shock protein 60
hsCRP – high sensitivity C reactive protein
IWMI – inferior wall myocardial infarction
IWMI +PWMI – inferior and posterior wall myocardial infarction
MI – myocardial infarction
PCI – percutaneous coronary intervention
PWMI – posterior wall myocardial infarction
RDA – recommended dietary allowance
STEMI – st elevation myocardial infarction
T2DM – type 2 diabetes mellitus
0‐ 18‐45 yrs 0‐MALE 0‐NO 0‐NO I 1‐INACTIVE 0‐NO 0‐NO 0‐NO 1‐AWMI 1‐CLASS I 0‐NO 0‐NO LVD 0‐NO RWMA 0‐NOT DONE 0‐NO LESION 0‐AMA 0‐NOT DONE
1‐46‐80yrs 1‐FEMALE 1‐YES 1‐YES II 2‐MINIMALLY ACTIVE 0‐NO 0‐NO 0‐NO 1‐SMOKER  0‐ NO 1‐MILD 1‐OVER WEIGHT 2‐AW+LWMI 2‐CLASS II 1‐YES 1‐MILD LVD 1‐LAD 1‐MEDICAL 1‐SVD 1‐LAD 1‐DEATH 0‐NO 1‐OUTSIDE
ELEVATED ELEVATED III 3‐HEPA ACTIVITY 0‐As per RDA 1‐YES 1‐YES 1‐YES 2‐ALCHOL 1‐ YES 2‐MODERATE 2 ‐ OBESE 3‐IWMI 3‐CLASS III 2‐MODERATE LVD 2‐RCA 2‐CABG 2‐DVD 2‐LCX 2‐DISCHARGED 1‐YES 2‐INHOSPITAL
>0.5MG/DL >2NG/ML IV 1‐More than RDA 2‐NOT KNOWN 3‐BOTH 3‐SEVERE 4‐PWMI 4‐CLASS IV 3‐SEVERE LVD 3‐LCX+RCA/ 3/3*‐PRIMARY/ELECTIVE* 3‐TVD 3‐RCA 3‐DISCHARGED 2‐CHRONIC 3/3*‐STREPTOKINASE/ALTEPLASE
V 2‐Less than RDA 5‐IW+PWMI 4‐LVDD 4‐LAD+RCA            PTCA     AT REQUEST 4/4*‐FAILED/COMPLICATIONS*
S No. Patient Name Age Sex HSCRP HSP 60 SOCIO ECO PHYSICAL ACTIVITY Diet T2DM SHTN Dyslipidemia Habits Family History Stress Obesity ACS Killip Class PRESENTING BP PRESENTING PR COMPLICATIONS ECHO ECHO CAG CAG CAG OUTCOME INFECTION OTHERS THROMBOLYSIS
1 Meenashi 1 1 0 1 II 1 0 0 1 1 0 0 2 2 1 1 140/90 96 0 1 1 2 3 1,2,3 2 0 0
2 Puspharaj 1 0 1 0 III 1 2 1 0 1 1 1 2 1 1 1 150/80 76 0 4 1 1 3 1,2,3 2 0 CIN 0
3 Mani 1 0 1 1 III 1 2 1 1 1 3 1 1 0 1 3 160/100 77 0 2 1 3* 1 1 2 0 Mild Renal Failure 4
4 Manickam 1 1 1 1 IV 1 1 0 0 1 0 1 2 1 3 2 130/90 74 1 ‐MR 2 2 0 0 0 0 0 0
5 Subramaniam 1 0 1 1 II 1 1 1 1 2 3 0 2 1 3 4 NOT RECORDABLE NOT FELT 1‐CARDIAC ARREST 3 0 0 0 1 1 CPR 0
6 Ganesan 1 0 0 0 II 2 1 0 1 1 3 1 1 2 1 2 120/100 64 0 1 1 3* 1 1 2 0 2,3
7 Kandasamy 0 0 0 1 IV 2 1 0 0 1 3 0 2 1 1 3 100/80 100 1‐ISCHEMIC VT/VF 1 1 1 0‐RECANALISED 1 2 0 2,3
8 Nagaraj.P 0 0 0 1 I 2 0 0 0 1 1 0 0 0 1 1 90/60 68 1 1 3 1 1 2 0 0
9 Suppathal 1 1 0 0 I 0 0 0 1 1 0 1 1 2 3 1 130/80 74 0 0 0 2 0 ANEMIA,HYPOTHYROIDISM 0
10 Ganesh.T 1 0 0 0 II 2 1 0 0 1 3 0 0 1 1 1 120/70 68 4 0 1 0‐RECANALISED 1 2 0 CAD 0
11 Palanisamy.N 1 0 1 1 I 1 1 0 1 1 1 0 0 2 1 2 100/80 81 2 4 3* 2 1,2 2 0 2,3
12 Natchammal 1 1 1 1 I 1 0 0 0 1 0 0 1 0 5 2 90/50 56 2:1 BLOCK,CHB 3 2 1,3 1 0 0
13 Selvam 0 0 1 1 II 1 0 0 0 1 0 0 1 1 3 1 80/60 65 1 2 0 2 0 0
14 Dhandapani 1 0 0 0 III 1 1 1 1 1 0 1 1 2 1 1 100/70 84 2 1 3 1 1 2 0 0
15 Chandrasekhar 0 0 1 0 II 1 0 1 0 1 3 0 1 2 1 2 130/70 92 POST THROMBOLYTIC BLEED 1 1 3 1 1 2 0 1,3*
16 Kumarasamy.R 1 0 0 0 II 2 1 1 0 1 1 0 0 1 3 1 100/60 98 2 3 3* 3 1,2,3 2 0 IHD,LEFT UL GRANULOMA BENIGN 2
17 Ravi.M 0 0 0 0 I 1 2 1 0 1 0 0 3 2 1 1 120/90 96 1 1 3 1 1 2 0 0
18 Chandran.B 0 0 1 1 II 1 2 1 1 1 3 0 2 1 3 2 110/70 124 VT/CHB SECOND TIME 2 2 3 3 1,2,3 2 0 CAD 2
19 Salaudeen 1 0 1 1 III 1 1 1 1 1 1 0 1 1 1 1 110/70 96 3 1 2 3 1,2,3 2 0 BRONCHIAL ASTHMA,SARIDON AL 0
20 Solomon.A 0 0 0 0 II 1 2 0 0 1 0 0 2 1 3 1 120/70 76 1 2 0 2 0 0
21 Jacob Augustine 1 0 0 1 I 1 1 0 0 1 2 0 2 2 4 2 70/50 162 1 2 1 3 1,2,3 2 0 CAD 0
22 Ramesh Kumar 0 0 0 0 III 1 0 0 1 2 3 1 NOT AVAILABLE 1 1 4 130/90 68 CARDIOGENIC SHOCK 0 0 CARDIAC SHOCK,INTUBATED
23 Gnanpoo 1 1 1 0 IV 1 0 1 0 2 0 0 NOT AVAILABLE 0 1 2 80/40 95 2 1 0 0
24 Joseph Chandran 1 0 1 1 I 1 2 1 0 1 0 1 3 1 1 1 140/90 80 1 1 1 1 1 2 0 BRONCHIAL ASTHMA 2,3
25 Ganapathy 1 0 1 0 II 2 0 1 1 1 1 0 0 1 2 2 90/50 100 MR,PAROXYSMAL AF 2 3 2 1 HCAP 0
26 Subramaniam* 1 0 1 1 IV 1 1 1 1 1 3 1 3 2 1 2 100/50 98 MR 2 1 2 3 1,2,3 1 1,2 HEPATITIS B,SEPSIS 1,3
27 Subbappa 1 0 0 0 I 1 1 1 1 1 3 1 1 1 1 2 110/80 91 MR 2 2 1 3 1,2,3 2 0 D2 TOTAL OCCLUSION‐POBA DONE 0
28 Vellingiri.P 1 0 1 0 IV 1 1 1 1 1 0 0 3 2 1 2 150/100 135 1 1 3 0 0
29 Sennimalai Gounder 1 0 0 0 II 1 0 1 1 2 1 1 NOT AVAILABLE 1 1 2 VT ,REVERTED 1 1 1 0 0
30 Thimmasamy 1 0 1 0 IV 1 0 0 1 1 1 1 2 0 1 1 110/60 92 1 1 3* 2 1,2 2 1 lower respiratory infection 1,3*
31 Valliammal 1 1 1 0 II 1 0 1 1 1 0 0 2 2 3 2 130/80 48 MR 2 2 1 3 1,2,3 2 0 MENINGIOMA 0
32 Krishnasamy.T 1 0 1 0 I 1 1 1 0 1 0 1 1 2 3 2 100/50 100 1 2 2 0 MILD RF/RT CONTRACTED KIDNEY 2,3
33 Rajendiran.A 1 1 0 1 II 1 1 1 0 1 2 1 2 1 3 1 130/100 79 MR,MVP‐PML 4 1 1 1 1 0 0 SUBCLINICAL HYPOTHYROIDISM 0
18 15 0 38 27 19 17 37 42 14 44 40 61 58 0 2713 0 54
0‐18‐45yrs 0‐Male I‐>5571 1‐INACTIVE 0‐NO
1‐46‐80yrs 1‐Female 0‐NO 0‐NO II 2‐MINIMALLY ACTIVE 0‐AS PER RDA 0‐NO 0‐NO 1‐MILD 0‐NO 0‐NO
1‐YES 1‐YES III 3‐HEPA ACTIVE 1‐MORE THAN RDA 0‐NO 0‐NO 0‐NO 1‐SMOKER 1‐YES 2‐MODERATE 1‐OVERWEIGHT 1‐YES
IV 2‐ LESS THAN RDA 1‐YES 1‐YES 1‐YES 2‐ALCHOLIC 3‐SEVERE 2‐OBESITY
V ‐ < 836 3‐BOTH
S NPatient Name Age Sex HSCRP HSP60 SOCIOECO PHYSICAL ACTIVITY DIET T2DM SHTN DYSLIPIDEMIA Habits Fam his Stress Obesity Others RECENT INFECTION
1 Bhavani MR 1 1 Y N I 1 2 0 0 1 0 1 0 1 Asthmatic 0
2 Sundarambal 0 1 N Y III 1 0 0 0 1 0 0 1 0 Occasional pain killer 1
3 Mani.P 1 0 Y Y III 1 1 0 0 1 0 0 1 1 0
4 Soundarajan.P 1 0 N N I 1 1 1 0 1 0 1 0 1 ? Skin Allergy 0
5 Sundaram.M 1 0 N Y I 1 0 0 1 1 1 0 0 1 Not on anti htn drugs 0
6 Gurusamy.K 0 0 N N II 1 1 0 0 1 3 0 0 1 Renal calculi 0
7 Chinnasamy 0 1 N N II 1 0 0 0 1 0 0 1 0 0
8 Soby.C.I 0 0 N N I 1 1 0 0 1 2 0 1 1 0
9 Praveen Chakrav 0 0 N N II 1 0 0 0 0 0 0 3 0 0
# Velayudham K 0 0 N N I 2 0 0 0 1 2 0 0 0 0
# Subramaniam 1 0 N Y II 1 1 1 0 1 2 0 1 1 1
# Senthilkumar.P 0 0 Y N II 1 1 1 1 1 2 0 1 1 Not on drugs for HTN/T2DM 0
# Sarasvathi.T 1 1 N N I 1 0 0 0 1 0 1 1 0 0
# Hemanthkumar.R 0 0 N N I 1 0 0 0 1 0 0 2 2 0
# Umarani 1 1 Y Y I 2 0 1 0 1 0 0 1 1 0
# Subbulakshmi 0 1 N N IV 3 2 0 0 1 0 0 0 0 0
# Sumathi.G 0 1 N N I 2 1 1 0 1 0 0 1 1 On Siddha medication 0
# Sivasamy.T 1 0 N N II 1 0 0 0 1 0 0 0 1 0
# Samuel Mani.P 1 0 N N I 1 1 0 0 1 2 0 0 2 0
# Sujin.R 0 0 N N I 1 1 0 0 1 0 0 1 1 Childhood Tb‐treated 0
# Harikrishnan.M 0 0 N Y I 1 0 0 0 1 0 0 0 0 0
# Amit Kumar 0 0 N N I 2 0 0 0 0 3 0 2 1 H/O Hyperthyroidism 0
# Amutha.H 0 1 Y Y I 1 1 0 0 0 0 0 1 0  RA,ON STEROIDS AND DMARDS 0
# Ranganayagam.G 1 1 N Y III 1 2 0 0 1 0 0 0 0 0
# Murugesan.N 1 0 Y N II 2 0 0 0 1 1 1 1 1 0
# Selvi 0 1 Y N I 1 2 0 0 0 0 1 0 1 0
# Padmavathi 0 1 N N I 1 1 0 0 1 0 1 0 1 0
